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Abstract
Obesity has become a global public health problem and is a major risk factor for type 2
diabetes. Ghrelin is an appetite-stimulating hormone which acts through its receptor on the
hypothalamus to regulate energy balance and thus plays a major role in the aetiology of
metabolic diseases.
The aims of the studies conducted were 1) to investigate possible associations between
single nucleotide polymorphisms (SNPs) in the ghrelin (GHRL) and ghrelin receptor (GHSR)
genes and obesity, type 2 diabetes or related phenotypes in persons with impaired glucose
tolerance participating in the Finnish Diabetes Prevention Study, 2) to study the role of
circulating ghrelin concentrations in the context of metabolic disturbances and 3) to evaluate
the possibility of ghrelin gene expression in peripheral blood mononuclear cells (PBMCs) for
use as a surrogate marker for ghrelin metabolism.
SNPs were genotyped using either a restriction fragment length polymorphism technique
or TaqMan allelic discrimination assays. The Leu72Met SNP in GHRL was associated with
type 2 diabetes. A common genotype combination of GHRL SNPs was associated with low
blood pressure levels and lower risk of hypertension. The rs490683 SNP in the 5’-region of
GHSR was associated with weight loss and disrupts a putative binding site for the
transcription factor nuclear factor-1. Further gelshift experiments conducted with nuclear
extract from rat hypothalamus showed higher protein binding to the minor G allele of the
rs490683 SNP in vitro, which could lead to increased GHSR expression and thus increased
food intake in persons with the risk allele. Ghrelin plasma concentrations were not restored by
weight loss in persons with the metabolic syndrome; instead, those in the control group
showed a further decrease in ghrelin levels. GHRL and GHSR were expressed in PBMCs but
were not altered upon metabolic changes or associated with certain phenotypes. Thus, ghrelin
expression in PBMCs seems unsuitable as a surrogate marker for ghrelin metabolism during
lifestyle changes. Nevertheless, ghrelin expression correlated with the expression of pro-
inflammatory cytokines, suggesting that ghrelin may play a role as an autocrine factor in the
immune system.
In conclusion, SNPs in the GHRL gene may indicate a risk of hypertension, one of the
features of metabolic syndrome; however, variations in GHRL seem not to be strong risk
factors for type 2 diabetes or obesity. Genetic factors leading to increased GHSR expression
and thus potentially to increased ghrelin signalling might ultimately lead to an increase in
appetite and weight gain.
National Library of Medicine Classification: QZ 50, WK 810, WK 820
Medical Subject Headings: Diabetes Mellitus, Type 2/metabolism; Diabetes Mellitus, Type
2/etiology; Finland; Genetic Predisposition to Disease; Ghrelin/genetics; Ghrelin/metabolism;
Glucose Intolerance/genetics; Insulin Resistance/etiology; Metabolic Syndrome X;
Obesity/etiology; Polymorphism, Single Nucleotide; Public Health; Receptors,
Ghrelin/genetics; Risk Factors
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1 Introduction
Obesity has emerged as a pre-eminent public health problem. The prevalence and incidence of
overweight and obesity are steadily rising worldwide. The so-called “obesity epidemic” gives
rise to a multitude of metabolic disorders, most notably type 2 diabetes, for which obesity is a
strong risk factor. Obesity, and especially abdominal obesity, is believed to be the core of the
metabolic syndrome, composed of a range of metabolic abnormalities, including insulin
resistance, dyslipidaemia, hypertension, impaired glucose tolerance and type 2 diabetes.
Obesity is a complex disease caused by the interplay between environmental and genetic
factors. Generally speaking, overweight and obesity are caused by an imbalance in energy
input and energy expenditure, with the major environmental factors involved in obesity being
dietary and physical activity habits, which act in conjunction with predetermined genetic
parameters. Obesity is a multifactorial disease, the onset of which is influenced by
susceptibility genes interacting with each other and influencing environmental factors through
determinants such as energy expenditure, fuel metabolism, muscle fibre function and appetite
or food preferences. Body weight is regulated by long-term and short-term energy balance
signals. Energy homeostasis is controlled by peripheral signals from adipose tissue, the
pancreas and the gastrointestinal tract. These signals influence circuits in the hypothalamus
and brain stem to produce positive and negative effects on the energy balance.
One of the gut-derived peptides involved in the regulation of energy balance is ghrelin.
Ghrelin was originally discovered as a natural growth hormone secretagogue. Subsequently, it
was noted that ghrelin acts as an appetite stimulator and a meal initiator and was therefore
called the first “hunger hormone”. This peptide is produced by the stomach and circulates in
the blood stream. Ghrelin acts in the hypothalamic arcuate nucleus, the centre of weight
control in the brain, through its receptor to enhance expression of potent appetite stimulants.
In the present work, the role of ghrelin in obesity and insulin resistance was investigated
1) by studying genetic variations of ghrelin and its receptor in association with obesity and
type 2 diabetes, 2) by examining the expression of ghrelin and ghrelin receptors in peripheral
blood mononuclear cells and subcutaneous adipose tissue and 3) by investigating the possible
impact of lifestyle modification on ghrelin expression and circulating levels of ghrelin.
16
17
2 Review of literature
2.1 Ghrelin
In December 1999, ghrelin was first reported as an endogenous ligand for the former orphan
receptor growth hormone secretagogue receptor (GHSR) 1a [1]. Until then, only synthetic
growth hormone secretagogues (GHS), compounds that are potent stimulators of growth
hormone (GH) release, were known to stimulate the GHSR. Ghrelin was purified from the rat
stomach, and the ghrelins in rats and humans were found to differ in only two amino acid
residues [1, 2]. Ghrelin exists in several mammalian, avian and fish species [2]. The amino
acid sequences of mammalian ghrelins are well conserved, especially the NH2-terminal region
with its unique fatty acid modification, indicating that this region is of central importance for
the activity of the peptide [2]. Ghrelin shows high homology to motilin, in a manner similar to
the high homology shown by GHSR to the motilin receptor [2], suggesting that the ghrelin
and motilin systems may have evolved from a common ancestral system. A few months after
ghrelin’s discovery by Kojima et al. [1], Tomasetto et al. [3] reported the identification of a
gastric peptide named motilin-related peptide that has an amino acid sequence identical to that
of ghrelin.
2.1.1 Gene and precursor structures of ghrelin
Figure 1 describes the processing of the human ghrelin gene (GHRL) into the active ghrelin
peptide. The human GHRL gene is located at chromosome 3p25-26 and consists of five exons
and four introns [4]. The short first exon contains only 20 bp and is present in the noncoding
region of the human GHRL [4]. There are two different transcriptional initiation sites,
resulting in two distinct mRNA transcripts, of which one is the main form of human ghrelin
mRNA in vivo [4]. The mRNA is translated into a precursor peptide (prepro-ghrelin), with
protease cleavage and acyl-modification of the precursor resulting in a mature ghrelin peptide,
a 28-amino acid peptide esterified by an octanoyl group (C7H15CO) at the serine-3 (Ser3)
residue [1]. Acylation is necessary for ghrelin to bind to its receptor GHSR 1a [5], GH-
releasing activity in vivo, [6] as well as other central and peripheral endocrine and non-
endocrine actions [7, 8] of the peptide. The modification also determines the extent and the
direction of ghrelin transport across the blood-brain barrier (BBB) [9]. The enzyme which
attaches the octanoyl group to Ser3 of ghrelin has been recently identified and named GOAT
(Ghrelin O-Acyltransferase) [10].
2.1.2 Regulation of GHRL transcription
The 5’-flanking region of the human GHRL contains a TATA box-like sequence, though
reports on its functionality are controversial [4, 11, 12]. Putative binding sites for several
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transcription factors (TF), such as activator protein-2 (AP2), basic helix-loop-helix (bHLH),
PEA-3, Myb, NF-IL6, hepatocyte nuclear factor-5, NF-?B, and several E-box consensus
sequences, and half-sites for oestrogen and glucocorticoid response elements have been found
[4, 11, 12]. Studies of ghrelin promoter activity in different cell lines recognized several
different activating sequences within 2000 bp upstream of the translation initiation site,
suggesting a cell-type-specific activity for the human ghrelin promoter [4, 12, 13]. Recently,
one single nucleotide polymorphism (SNP) 1062 bp upstream of the translation initiation site
has been reported to disrupt the binding site for the TF MyoD, a bHLH TF, with this sequence
variation resulting in lower promoter activity in the luciferase reporter gene assay [14].
Figure 1. Conversion from the human GHRL gene into an active peptide (modified from Kojima and
Kangawa 2005 [2]).
  , non-coding exon 1;   , untranslated region;   , signal peptide;   , ghrelin;   , cleaved from mature form
1 kb
Exon 1
Ghrelin
Chromosome 3p25-26
GSSFLSPEHQRVQQRKESKKPPAKLQPR
O=C-(CH2)6-CH3
O
n-octanoyl ghrelin
2 3 4 5
Human
GHRL
Transcription
Splicing
Mature Ghrelin
mRNA
Ghrelin precursor
(prepro-ghrelin)
Translation
1 117
1 28
Cleavage and acyl-modification
Alternative transcript includes
the non-coding exon 1
Cleavage sites
NH2 COOH
Obestatin
24 51 76 98
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2.1.3 Structural variants of ghrelin
2.1.3.1 Des-acyl ghrelin
Ghrelin has a unique fatty acid chain on its N-terminal end. However, the majority of
circulating ghrelin actually lacks this acyl group and is known as des-acyl or des-octanoyl
ghrelin (non-acylated or unacylated ghrelin). In the blood stream, acylated ghrelin is present
at a 2.5 fold lower concentration than des-acyl ghrelin [15]. Des-acyl ghrelin was initially
assumed to be an inactive peptide, since it had been shown to lack the ability to bind to the
GHSR 1a [16] and showed no GH-releasing activity in vivo in rats or humans [1, 2, 17].
However, recent research shows that des-acyl ghrelin has physiological effects that are
mediated by unknown receptors other than GHSR 1a and thus des-acyl ghrelin may be
considered a metabolically active peptide affecting glucose and lipid metabolism and possibly
food intake and appears to interact with acylated ghrelin in the control of metabolism, thus
having non-endocrine activities [2, 18, 19].
2.1.3.2 Des-Gln14-ghrelin
Naturally occurring variants of ghrelin include an alternative splice variant des-Gln14-ghrelin,
which lacks Gln at residue 14 [20]. Des-Gln14-ghrelin has been purified from rat and mouse
stomach and was found in circulation with the same biological activities as ghrelin [20, 21],
but whether it exists in humans as well is unclear [2]. In rodent experiments ghrelin and
des-Gln14-ghrelin have been shown to stimulate gastric emptying in a dose-dependent
manner while des-acyl ghrelin and motilin lack this effect. The C-terminally truncated ghrelin
fragments (ghrelin-18, -10 and -5) are effective but much less potent than ghrelin itself.
Ghrelin, des-Gln14-ghrelin and des-acyl ghrelin neither stimulated nor inhibited gastric acid
secretion [22].
2.1.3.3 Other variants
In humans, multiple ghrelin-derived molecules differing in their acyl groups on Ser3
(decanoyl (C10:0) or decenoyl-esterified (C10:1) molecules) have also been isolated from the
stomach and circulation [23]. These acyl-modified ghrelins are capable of stimulating GH
release in rats to a degree similar to that of octanoylated ghrelin [23], and peptides with 27
amino acids were found that lack the C-terminal Arg28 [23].
2.1.3.4 Obestatin
It was recently discovered that another putative peptide hormone derives from the same pro-
protein as ghrelin, obestatin. The 23-amino-acid polypeptide obestatin was initially reported
to be the endogenous ligand for the orphan receptor G protein-coupled receptor 39 (GPR39)
and to act as an appetite suppressant [24-26]. However, recent reports indicate that obestatin
is unlikely to be the endogenous ligand for GPR39 [27-30].
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2.2 Tissue distribution of ghrelin
Ghrelin is expressed primarily by the stomach and secondarily by the lower gastrointestinal
tract (small and large intestine). Ghrelin expression levels in other organs are relatively low in
comparison, and it might have physiological relevance as a paracrine or autocrine factor in
these tissues. An endocrine role for extra-gastrointestinal ghrelin appears to be unlikely [18].
2.2.1 Stomach and gastrointestinal organs
Ghrelin was originally isolated from the stomach [1]. There are a number of different types of
endocrine cells in the stomach, of which ghrelin-containing cells form a distinct cell type
found in the mucosal layer of the stomach [31, 32]. Ghrelin has been localized in the oxyntic
glands, specifically in the X/A-like cells of the gastrointestinal tract. These ghrelin-producing
cells account for about 20% of the endocrine cell population in the human oxyntic mucosa
[31]. Ghrelin cells develop during early foetal life [32] and are characterised by round,
compact, electrondense granules that are filled with ghrelin [2, 31, 32]. Ghrelin cells are also
found in the duodenum, jejunum, ileum, and colon [33], with the ghrelin concentration
gradually decreasing from the duodenum to the colon [8].
Circulating ghrelin levels mostly reflect gastric secretion; in fact, they are reduced by
70% after gastrectomy [34]. After total gastrectomy, ghrelin levels gradually increase again,
suggesting that the stomach is the major source of circulating ghrelin, though other tissues
may compensate for the loss of ghrelin production after gastrectomy [35].
2.2.2 Endocrine pancreas
Expression of ghrelin in the human pancreatic islet remains somewhat controversial because it
has variably been reported to be present in the ? cells [36] or ? cells [37], and it has been
suggested that ghrelin cells may constitute a new islet cell type [38, 39]. Ghrelin is expressed
in foetal, neonatal, and adult human pancreatic islets and is upregulated during development
[32, 38]. It is anticipated that ghrelin may play a role in modifying pancreatic ? cell function.
The exact function of ghrelin within the islets is still unknown, but it may have a paracrine
role in regulating insulin secretion or glucose metabolism.
2.2.3 Brain
Ghrelin has been detected in the hypothalamic arcuate nucleus (ARC) of the rat brain [1, 40-
42]. In addition, it has been reported that ghrelin is present in hypothalamic neurons adjacent
to the third ventricle between the dorsal, ventral, paraventricular and arcuate hypothalamic
nuclei [43]. In humans, ghrelin expression was found in six different brain regions, namely
frontal cortex, temporal cortex, visual cortex, pons, medulla, and hypothalamus [44]. In
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addition, ghrelin expression in the hypothalamus was shown to be higher in obese than in lean
persons [45].
2.2.4 Other tissues
Ghrelin mRNA has been detected very widely at low levels. Ghrelin mRNA and peptide are
synthesized locally within the anterior pituitary gland [46-48]. In human placenta, ghrelin
appears to be mainly expressed in the first half of pregnancy, whereas it could not be detected
at term [49]. Human ghrelin mRNA expression was shown in T-lymphocytes, B-lymphocytes,
and neutrophils from venous blood of healthy volunteers [48, 50, 51] as well as in
subcutaneous and visceral adipose tissue with large intraindividual variations [52]. Ghrelin
was also detected in human ovaries and testis [48, 53-55]. Furthermore, ghrelin is present in a
number of different tumours including neuroendocrine tumours, pituitary adenomas,
endocrine tumours of the pancreas, breast tumours and thyroid and medullary thyroid
carcinomas [56].
2.3 Regulation of ghrelin plasma concentration
Numerous studies have been conducted on the possible factors influencing plasma ghrelin
concentrations. The following chapter reviews the most important and most discussed factors.
Most studies have investigated plasma total ghrelin concentrations (acylated and des-acyl
ghrelin together). However, when acylated and/or des-acyl ghrelin levels have been measured
separately, this will be pointed out. Table 1 summarises some of the factors influencing total
and acylated ghrelin plasma concentrations.
Table 1. Factors affecting total and acylated ghrelin concentrations.
Factors Total ghrelin Acylated ghrelin
Dietary components:
Carbohydrates ? [57-64]
? [65]
? [61-65]
Fat ? [57, 58, 64, 66]
? [60]
? [62, 64]
? [61, 67]
Protein ? [63, 64, 68]
? [66]
? [58, 60]
? [62-64, 67]
Glucose ? [69-72] -
Insulin ? [73, 74] -
Leptin negative correlation [75-78]
no correlation [79-82]
? [78]
-
Exercise ? [83-92]
? [86, 93]
? [90]
?, decrease; ?, no change; ?, increase; -, no studies available
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2.3.1 Fasting and food intake
Circulating plasma ghrelin levels show a diurnal pattern with preprandial increases and
postprandial decreases, resulting in a characteristic secretion pattern [71, 94]. Moreover,
acylated ghrelin falls after ingestion of a balanced meal [67, 95]. Interestingly, even in fasting
subjects, a characteristic diurnal course with spontaneous rises and declines at customary
mealtimes occurs when food is anticipated, regardless of whether it is actually later received,
nor has a marked change been found in insulin or glucose levels [96, 97]. This may suggest
that preprandial ghrelin secretion may represent some type of conditioned physiological reflex
[96]. However, it has been observed that prolonged fasting in healthy subjects results in an
overall decrease in ghrelin levels [96-98].
The volume of the ingested meals is rather unlikely to have an effect on plasma ghrelin
levels, as it has been shown that gastric distension (by water or guar solution) has no effect on
plasma ghrelin levels [58, 71, 99]. Instead, the extent of the ingested caloric load seems to
determine the postprandial suppression of plasma ghrelin [100]. Moreover, cephalic vagal
activation modified by sham feeding (chew and spit) do not contribute to the postprandial
alterations of plasma ghrelin levels [58].
The effects of individual macronutrients on postprandial ghrelin concentration have been
intensively studied, though these studies are not always consistent. Total and acylated ghrelin
levels decrease after carbohydrate-rich test meals [57-65]. The initial decrease is followed by
a subsequent increase back to the basal levels in the late postprandial and interdigestive period
[58, 61, 64]. Only one report has failed to show a decrease in total ghrelin after consumption
of a carbohydrate-rich liquid meal [65]. Given this rise in ghrelin plasma levels before meal
intake and a fall thereafter, it has been proposed that this pattern might contribute to early
postprandial satiety. The early postprandial reduction in circulating ghrelin would attenuate
the hormonal gastric feeding drive, thereby supporting neurally activated satiety signals. The
progressively increasing ghrelin levels during the later postprandial and interdigestive phase
back to baseline could then contribute to the recurrence of appetite and hunger sensations
[94]. However, no associations of postprandial total ghrelin [60, 63, 101, 102] or acylated
ghrelin concentrations [63] with measures of satiety have been obsvered. Only one study
showed a correlation between the increase in satiety and a decrease in ghrelin postprandially
[103].
It has been shown that a high-fat meal not only induces suppression in circulating ghrelin
[57, 58, 64, 66], but also increases the plasma ghrelin concentration postprandially [60].
Acylated plasma ghrelin either decreases after a high-fat meal [62, 64] or does not change [61,
67]. Protein intake has been reported to decrease [63, 64, 68], increase [58, 60] or not to affect
[66] circulating ghrelin levels, while acylated plasma ghrelin has been shown to decrease after
a high-protein meal [62-64, 67].
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2.3.2 Glucose and insulin
Insulin has an inhibitory influence on total ghrelin levels in healthy normal-weight [74, 104]
and overweight [105] persons during euglycaemic hyperinsulinaemic clamp with
pharmacological insulin concentrations. Total ghrelin is also suppressed by insulin at
concentrations that resemble those seen in insulin-resistant subjects [73, 106-109], in healthy
normal-weight persons and in obese subjects [110], although others have reported
controversial findings [104]. Acyl-ghrelin has been shown to be decreased by insulin in type 2
diabetic patients [111] and in insulin sensitive overweight patients [105] in studies using
insulin in pharmacological doses, but not in insulin resistant overweight subjects [105] or in
normal-weight persons using a lower dose of insulin infusion [106].
It has been suggested that postprandial hyperinsulinaemia may be responsible for the
reduction in plasma ghrelin that occurs after meal intake, and it has been shown that insulin is
required for prandial suppression of ghrelin [112]. However, further studies indicate that other
metabolic factors are likely to be involved in postprandial ghrelin suppression [113].
Both oral and intravenous glucose loads inhibit ghrelin secretion in humans [69-72]. An
increase in insulin after oral or intravenous glucose administration could contribute to the
inhibitory effect of glucose on ghrelin concentrations. However, the administration of a
combined pulse of glucose and insulin does not acutely suppress ghrelin levels [72]. An
intravenous glucose bolus reduces ghrelin both in controls and in subjects with type 2
diabetes, which may suggest that early insulin response may have no effect on plasma ghrelin,
since early insulin response to intravenous glucose infusion is abolished in patients with type
2 diabetes [114].
The exact mechanisms by which variations in insulin and glucose concentrations regulate
ghrelin secretion are still unknown, and it is unclear whether insulin or glucose per se plays a
direct inhibitory role in ghrelin secretion [72, 104]. Furthermore, the decrease in ghrelin levels
after an oral glucose load is modulated by such factors as sex, obesity status and level of
insulin resistance [66].
2.3.3 Leptin
It has been suggested that leptin may constitute a possible determinant of circulating ghrelin
concentrations [115], as chronic leptin administration has been shown to upregulate ghrelin
mRNA expression in the gastric fundus in rats [116]. Leptin is released from adipocytes as a
function of the amount of fat, and in concert with the leptin produced locally in the
hypothalamus, engages distinct hypothalamic effector pathways to restrain appetite and
augment energy expenditure, acting in an opposite manner to that of ghrelin [117-119]. An
inverse relationship between ghrelin and leptin concentrations has been reported by some
studies [75-78], whereas others were unable to show such an association [79-82]. One study
showed an inverse relation between circulating leptin and ghrelin in lean subjects and no
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correlation in obese subjects [120]. Furthermore, administration of recombinant leptin has no
effect on plasma ghrelin concentrations in normal-weight subjects [78].
2.3.4 Exercise
Studies investigating the effect of exercise on circulating ghrelin levels have been inconsistent
[121]. Acute exercise may induce an acute negative energy balance. Short-term exercise trials
have investigated the immediate effect of aerobic or resistance exercise load on ghrelin levels.
Most studies investigating ghrelin response suggest that exercise alone may not alter ghrelin
concentration in adults [83-89, 91, 92], whereas others have shown an increase after exercise
[86, 93]. In another study, total ghrelin was unaffected by short-term exercise, whereas
acylated ghrelin increased [90].
2.3.5 Sex
There are studies showing higher plasma total ghrelin levels in women than in men [66, 122-
124], while acylated ghrelin has been reported to be comparable among genders [124, 125]. In
contrast, acylated as well as des-acyl ghrelin levels have also been reported to be higher in
women compared to men [125, 126]. Most studies have not specifically reported on a
difference between males and females in their studies, thus it may be presumed that they have
observed no difference, whereas others have specifically pointed out that they observed no
difference between genders [79, 127].
2.3.6 Age
Plasma total and acylated ghrelin levels have been reported to be lower with increasing age
[125, 128, 129], while no age-related variation has been shown with des-acyl ghrelin [125].
Despite these findings, the vast majority of reports have remained unable to detect a
difference in ghrelin levels for different age groups [122, 127, 130-133], while only one study
reports a positive correlation between ghrelin concentration and age [94].
Different levels of obesity could influence the relationship between ghrelin and age. Older
women showed lower ghrelin levels only within the lean group, whereas the overweight and
obese groups showed no difference between younger and older persons. Furthermore, only the
ghrelin levels of young women decreased with increasing levels of obesity, while no
association was seen in older women [128]. In addition to BMI, other modifying factors, such
as menopause, should be considered as possibly affecting plasma acylated, des-acyl or total
ghrelin levels in women, as markedly higher ghrelin levels have been recently shown in the
perimenopause stage compared to both premenopause and postmenopause stages [134].
Oestrogen replacement therapy has been shown to increase plasma levels of acylated ghrelin
[135].
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2.4 The ghrelin receptor
2.4.1 Ghrelin receptor family
Howard et al. [136] cloned a G protein-coupled receptor of the pituitary and hypothalamus of
humans and swine and showed this receptor to be the target of GHSs, a class of peptide and
non-peptide compounds leading to GH release from the anterior pituitary. Until the discovery
of ghrelin in 1999 [1], GHSR was designated as an orphan receptor.
The GHSR is expressed by a single gene found at human chromosomal location 3q26.2
(Figure 2) [136, 137]. Two types of GHSR cDNAs, which are presumably produced by an
alternative splicing mechanism, have been identified and designated as receptors 1a and 1b
[136]. The GHSR gene consists of two exons: the first exon encodes transmembrane regions I
to V, and the second exon encodes transmembrane regions VI and VII. The human GHSR 1a
consists of 366 amino acids with 7 transmembrane regions (Figure 2). The cDNA for
GHSR 1b encodes a shorter form, which consists of 289 amino acids with only 5 predicted
transmembrane regions (encoded by exon 1) plus a unique 24-amino acid “tail” encoded by
an alternatively spliced intronic sequence using an alternate stop codon (Figure 2) [136, 138].
Multiple transcription start sites have been proposed for GHSR, with one major
transcription start site being located 227 nucleotides upstream from the translation initiation
codon and the other one located at -453 [138-140]. The proximal promoter region of the
GHSR gene does not have any of the typical characteristics of promoter regions, such as a
TATA box, CAAT box, or the GC-rich region, though consensus sequences have been found
for initiator elements [138-140]. Putative binding sites for several TF were identified on the
GHSR promoter. These included putative binding sites for the enhancer factor AP-1,
consensus sequences for the nuclear factor 1 (NF-1), as well as consensus sequences for the
POU-domain TFs, Pit-1, Oct-1, and Ptx1, which have been shown to be involved in pituitary-
specific expression [138, 140]. Studies of GHSR promoter activity in different cell lines have
recognized several different repressor and enhancer elements within 3000 bp upstream of the
translation initiation site [138, 139].
The existence of an alternative novel unidentified subtype of ghrelin receptor has been
suggested by various studies using des-acyl ghrelin [141]. This putative subtype of ghrelin
receptor is distinct from GHSR 1a, but has the same binding affinity for des-acyl and acyl-
ghrelin as shown by competition binding studies using radiolabelled ghrelin in several cell
lines not expressing GHSR 1a [142-146]. In addition, central administration of des-acyl
ghrelin to GHSR-deficient mice was shown to stimulate feeding, while ghrelin treatment had
no effect on food intake, suggesting that des-acyl ghrelin acts through a target protein that is
specific for des-acyl ghrelin and independent of the known GHSR [147, 148].
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Figure 2. Schematic representation of the GHSR gene and amino acid sequence with proposed
two-dimensional structure of the human GHSR (constructed using data from the Swiss-Prot protein
knowledge database [http://ca.expasy.org/sprot/]; primary accession number Q92847).
   GHSR 1b cDNA includes 74 nucleotides of intronic sequence of GHSR 1a (   ).
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2.4.2 Ghrelin receptor activation
The binding of ghrelin and synthetic GHS to the GHSR 1a activates the phospholipase C
signalling pathway, leading to increased inositol (1,4,5)-trisphosphate (IP3) turnover, followed
by the release of Ca2+ from intracellular stores through stimulation of the G protein subunit
??11 [136]. The intracellular rise in free Ca2+ provokes depolarization of the somatotropes and
release of GH [136, 149, 150]. Unlike the GHSR 1a, the GHSR 1b cDNA fails to bind
synthetic GHS and cannot be activated by GHSR ligands [136]. Thus, the functional role of
GHSR 1b remains to be defined. Nevertheless, since it is widely expressed in many normal
GHSR 1a-positive or -negative tissues [48], it is possible that this receptor possesses still
unknown biological functions.
In vitro studies have shown that short peptides encompassing the first four or five
residues of ghrelin were found to activate the human GHSR 1a almost as efficiently as the
full-length ghrelin, thus implying that the N-terminal Gly-Ser-Ser(n-octanoyl)-Phe segment
constitutes the “essential core” required for efficient binding to and activation of GHSR 1a [5,
151].
GHSR 1a exhibits high constitutive activity, when overexpressed in vitro [152]. GHSR 1a
signals with approximately 50% efficacy in the absence of an agonist [152, 153]. However,
the in vivo physiological importance of high ligand-independent signalling activity remains to
be determined. Furthermore, the constitutive activity has been shown in COS-7 (African
green monkey kidney), HEK293 (human embryonic kidney) and CHO-hGHS-R (Chinese
hamster ovary cells expressing human GHSR) cell lines, but not in the RC-4B/C (rat pituitary
tumour) cell line, which might indicate that GHSR 1a may be turned off or on depending on
the cellular context [150]. A recent report has revealed that GHSR 1b acts as a repressor of
the constitutive activity of GHSR 1a when overexpressed in vitro [154]. Thus GHSR 1b may
represent an endogenous candidate for the modulation of the activity of GHSR 1a. It has been
shown that GHSR 1b can form heterodimers with GHSR 1a, which may have functional
consequences [155]. Furthermore, when GHSR 1b expression exceeds that of GHSR 1a, this
leads to a decrease in cell surface expression of GHSR 1a, thus leading to attenuation in
GHSR 1a constitutive signalling [155].
2.4.3 Ghrelin receptor tissue distribution
GHSR 1a is highly expressed in central neuroendocrine tissues, such as the human
hypothalamus and anterior pituitary gland, consistent with its role in regulating GH release
[48, 136]. GHSR 1a expression has also been detected in human ovaries and testis [53, 54]
and human omental fat [156], as well as in the thyroid gland, pancreas, spleen, myocardium
and adrenal gland [48, 157, 158]. By contrast, GHSR 1b has been widely detected in
endocrine and non-endocrine human tissues [48]. In the rat, GHSR has been found in multiple
hypothalamic nuclei and in the pituitary gland [157].
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2.5 Physiological functions of ghrelin
2.5.1 Effects on food intake and regulation of energy homeostasis
In general, two systems operate in the regulation of food intake: short-term and long-term
regulation. Short-term regulation is concerned primarily with preventing overeating at each
meal, and long-term regulation is primarily related to maintaining normal quantities of energy
stores in the form of fat in the body [159]. Thus, body weight is regulated by a process of
energy homeostasis, whereby total energy intake and expenditure are closely matched over
long periods of time [160].
Feeding behaviour is regulated by complex mechanisms in the central nervous system
(CNS). The hypothalamus and the brainstem are the main brain regions responsible for the
regulation of energy homeostasis [161, 162]. They receive neural and hormonal signals from
the periphery that encode information about acute nutritional state and adiposity.
Mechanoreceptors and chemoreceptors in the gastrointestinal tract signal through the vagus
nerve to the brainstem. A number of hormones released from the gastrointestinal tract and its
associated structures stimulate ascending vagal pathways from the gut to the brainstem or act
directly on neurons in the brain [162].
The central pathways that regulate body weight in response to afferent information from
peripheral signals comprise a complex web of neuropeptides [161]. Catabolic neuropeptides
promote weight loss by decreasing food intake and increasing energy expenditure. Anabolic
neuropeptides promote weight gain by increasing food intake and decreasing energy
expenditure [160]. The ARC in the hypothalamus is highly important in the regulation of
feeding and appetite [161]. The anabolic neuropeptides neuropeptide Y (NPY) and agouti-
related protein (AgRP) are co-localized in ARC neurons, whereas the catabolic
proopiomelanocortin (POMC) is expressed in a distinct, but adjacent, subset of ARC neurons
[161]. These neurons exert opposing effects on the energy balance and are reciprocally
regulated by peripheral signals. POMC is cleaved into melanocortins including ? melanocyte-
stimulating hormone (?MSH), which exerts catabolic actions via melanocortin-4 receptors
(MC4R) [160, 163]. Arcuate POMC neurons co-express the cocaine- and amphetamine-
regulated transcript (CART), an anorexic neuropeptide that is regulated similarly to POMC by
alterations in energy stores. Arcuate NPY/AgRP and POMC neurons project to the lateral
hypothalamic area (LHA) which was denoted as a “hunger centre” [161]. Arcuate NPY/AgRP
and POMC neurons also signal to the paraventricular nucleus (PVN), which mostly sends
catabolic output [160, 161, 163, 164].
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2.5.1.1 Short-term energy balance and meal initiation
Ghrelin may play a role in meal initiation. Peripheral or central administration of ghrelin to
rodents stimulates short-term food intake and triggers eating at times of minimal spontaneous
food intake [165-168]. In humans, ghrelin administration enhances appetite and increases
food intake [169-171]. Moreover, a preprandial rise and a postprandial fall in plasma ghrelin
levels suggests a role for ghrelin as a physiological meal initiator [94, 172]. However, it is not
yet clear whether the preprandial rise in ghrelin levels does actually act to initiate eating or
whether ghrelin levels rise as a consequence of the expectation of food [94]; or possibly the
rise in ghrelin levels simply happens to coincide with meal times and is not directly related to
hunger or meal initiation at all [173]. One study, however, showed that ghrelin levels also rise
preprandially in humans in the absence of cues related to time or food [174].
2.5.1.2 Long-term energy balance
Ghrelin seems to be part of the body’s mechanism for controlling the long-term energy
balance. Peripheral daily administration of ghrelin causes weight gain by reducing fat
utilization in mice and rats, whereas intracerebroventricular administration generated a dose-
dependent increase in food intake and a subsequent increase in body weight [99]. Ghrelin also
increased feeding in GH-deficient rats, indicating that ghrelin modifies energy homeostasis
independently of its GH-releasing activity [165]. In humans, endogenous ghrelin levels are
negatively correlated with body weight and percentage of body fat [75, 175]. This is thought
to be physiologically relevant both in times of starvation and food shortage, when the elevated
ghrelin levels cause the body to be more energy-efficient [99] and conversely in situations of
positive energy balance, reduction in ghrelin secretion may reflect an adaptive counter-
regulatory response, to eat less and store less fat [176].
Centrally or peripherally administered des-acyl ghrelin has been shown to induce a state
of negative energy balance and to decrease body weight by inhibiting food intake in an
inverse manner to acylated ghrelin [177]. Others have shown a decrease in food intake upon
injection of des-acyl ghrelin [178, 179], whereas another study showed no alterations in
feeding after administration of des-acyl ghrelin to mice [180].
2.5.1.3 Mechanisms of action
Circulating peripheral ghrelin can exert effects directly, via the blood stream, by entering the
anterior pituitary gland and other areas of the brain not protected by the BBB [181], or
directly, by crossing the BBB via a saturable transport system [9]. The vagus afferent nerve
may be the major pathway conveying peripheral signals of ghrelin for starvation and GH
secretion to the brain [182].
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Ghrelin’s orexigenic action is independent of its GH-releasing activity and is mediated
via activation of neurons in the hypothalamic ARC that co-express the well-known orexigens,
NPY and AgRP and inhibition of POMC neurons (Figure 3) [183]. Almost all arcuate
NPY/AgRP neurons express the ghrelin receptor and can be stimulated by ghrelin, i.e.,
ghrelin induces c-fos expression, a marker of neuronal activation [165-167, 184]. The effect
of ghrelin in the hypothalamus is opposite to that of leptin. Leptin stimulates the POMC
anorexigenic pathway and inhibits the NPY/AgRP orexigenic pathway, resulting in reduced
food intake (Figure 3).
Figure 3. A simplified model of the feeding-regulatory signalling of ghrelin and leptin. (adapted from
Hosoda et al. 2002 [185])
NPY, neuropeptide Y; AgRP, agouti-related protein; POMC, proopiomelanocortin; ?MSH,
? melanocyte-stimulating hormone; MC4, melanocortin-4.
Furthermore, ghrelin has been shown to stimulate the metabolic regulatory enzyme
adenosine monophosphate-induced protein kinase (AMPK) in the hypothalamus [186, 187].
More recently, it has been demonstrated that ghrelin directly activates AMPK signalling in
NPY neurons in the ARC leading to activation of NPY neurons and thus potentially to
increased food intake [188]. AMPK acts as an intracellular energy sensor and maintains an
appropriate energy level in the cell [189], and activation of AMPK in the hypothalamus
increases food intake [187, 190].
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2.5.2 Growth hormone-releasing activity
Ghrelin possesses a strong and dose-related GH-releasing effect [1, 191-195]. In addition,
ghrelin potentiates growth hormone releasing hormone (GHRH)-dependent GH-secretion, that
is, co-administration results in more GH release than does either GHRH or ghrelin alone [194,
196]. The GH-releasing effect of ghrelin is most likely mediated via the vagus nerve [167,
182] and/or by direct action on the hypothalamus/pituitary region [197, 198].
The activity of ghrelin is not fully specific for GH, because it also includes stimulatory
effects on both the lactotroph and corticotroph system [191, 192, 194], and the
adrenocorticotrophin (ACTH) response to ghrelin is, in turn, followed by an increase in
cortisol and even aldosterone levels [194]. The effect of ghrelin on prolactin- and ACTH-
secretion is age- and gender-independent [199].
2.5.3 Effects on cardiovascular system
Ghrelin has diverse cardiovascular effects which are most probably GH-independent, since
expression of ghrelin receptor has been reported within the cardiovascular system [48, 200-
202]. Ghrelin has a vasodilatory effect in humans [203], showing a decrease in blood pressure
(BP) without an increase in heart rate [201] and additional haemodynamic effects by
increasing cardiac output [204]. Ghrelin exerts a therapeutic effect in heart failure [202, 205]
by improving left ventricular dysfunction and attenuation of the development of cardiac
cachexia in patients with chronic heart failure [206]. In addition, the ghrelin receptor shows
an upregulation and increased expression in the heart muscle of patients suffering from end-
stage heart failure [207].
In animal experiments, ghrelin has been shown to inhibit sympathetic activity and to
cause a decrease in arterial pressure [208, 209]. Furthermore, administration of ghrelin
improves endothelial dysfunction in rats [210]. It has been suggested that ghrelin, as well as
des-acyl ghrelin, act at the neurons of the nucleus of the solitary tract to suppress sympathetic
nerve activity and to decrease arterial pressure [208, 209, 211]. The nucleus of the solitary
tract, where baroreceptor and chemoreceptor afferents terminate, is one of the most important
brain regions to regulate BP and the sympathetic nervous system [212, 213].
Potential antiapoptotic effects of ghrelin and des-acyl ghrelin at the cardiovascular level
have been shown by inhibition of cell death of cultured cardiomyocytes and endothelial cells
[144]. In addition to the reports in vitro or in animals in vivo [21, 144, 211], there is evidence
of biological activity for des-acyl ghrelin in the human cardiovascular system, showing
beneficial cardiotropic effects and vasodilation in human arteries [214].
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2.5.4 Ghrelin and insulin secretion
In human studies, ghrelin has been shown to inhibit insulin secretion [215-217] and to
increase plasma glucose concentration [215, 217]. Similarly, acylated ghrelin has been
reported to induce a decrease in insulin and a rise in glucose levels [15]. Des-acyl ghrelin
alone seems to be devoid of any endocrine effects [17], though it is able to antagonize the
effects of acylated ghrelin on insulin secretion and glucose levels in normal human subjects
[15]. Furthermore, the combination of acylated and des-acyl ghrelin has been shown to
improve insulin sensitivity [218].
The hyperglycaemic effect of ghrelin may be mediated through activation of
glycogenolysis either indirectly by stimulation of catecholamine release or directly by acting
on hepatocytes, where it has already been shown to be able to modulate gluconeogenesis [19,
199, 219]. Acylated ghrelin stimulates glucose output by primary hepatocytes, whereas
des-acyl ghrelin has an inhibitory effect and, moreover, counteracts the stimulatory effect of
acylated ghrelin on glucose release [146]. In mice, ghrelin hampers the capacity of insulin to
suppress endogenous glucose production, whereas it reinforces the action of insulin on
glucose disposal; furthermore, simultaneous administration of des-acyl ghrelin abolishes the
inhibitory effect of ghrelin on hepatic insulin action [220]. However, a recent human study
showed that ghrelin infusion decreased insulin-stimulated glucose disposal and induced
peripheral insulin resistance, but did not affect hepatic insulin production [221].
Depending on the experimental conditions, ghrelin has been reported to be able to inhibit
or to stimulate insulin secretion in animals. Discrepancies may also reflect species
differences. Ghrelin stimulates insulin secretion from isolated rat and mice pancreatic islets
and in rats in vivo [36, 222-224]. Des-acyl ghrelin strongly stimulates insulin secretion by
pancreatic ? cells [225] and a rat insulinoma cell line [226]. However, ghrelin was also found
to inhibit glucose-induced insulin release in rodents [227, 228], and ghrelin seems to directly
inhibit insulin secretion in isolated islets in vitro [229, 230]. In vitro, des-acyl ghrelin
promotes survival of human islets of Langerhans [225] and prevents cell death and apoptosis
of pancreatic ? cells [231].
2.5.5 Immunomodulation
Given the wide distribution of functional GHSR in various immune cell subsets [51], it has
been hypothesized that ghrelin may exert immunoregulatory effects on immune cell
subpopulations [232]. In vitro, ghrelin treatment was shown to inhibit production of pro-
inflammatory cytokines (interleukin [IL]-1?, IL-6 and tumour necrosis factor [TNF]-?) by
peripheral blood mononuclear cells s(PBMCs) via a GHSR-specific pathway [51]. It has been
further reported that ghrelin inhibits IL-6 and TNF-? mRNA expression in primary human T
cells [51]. These findings support a role for ghrelin in the transcriptional regulation of
inflammatory cytokine expression [51].
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2.5.6 Effects on adipose tissue
Several studies suggest that ghrelin may play an important role in the process of adipogenesis
and storage of energy. As mentioned earlier, chronic ghrelin administration has been shown to
increase body fat content in rodents [99]. Ghrelin has been shown to inhibit AMPK in adipose
tissue, which could lead to increased lipid stores [186], thus potentially explaining the effect
of ghrelin on fat storage. Central ghrelin infusion in rats promotes glucose and triglyceride
(TG) uptake, increases lipogenesis and inhibits lipid oxidation in white adipocytes, whereas
central ghrelin infusion in brown adipocytes results in decreased expression of uncoupling
proteins, which usually contribute to energy dissipation. These effects seem to be mediated
via the sympathetic nervous system [233].
The stimulatory effects of ghrelin on adipogenesis have been shown in vivo in bone
marrow (for acylated and des-acyl ghrelin) [234] and in vitro on differentiated adipocytes
[235]. In different adipose tissue culture systems in vitro, ghrelin has been shown to stimulate
insulin-induced glucose uptake, whereas des-acyl ghrelin has no effect [236]. Furthermore,
ghrelin has been shown to mediate mitogenic and antiapoptotic effects through activation of
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)-Akt
pathways [142, 237], as well as having antilipolytic properties [238]. Additionally, des-acyl
ghrelin has been shown to act directly as antilipolytic factor on rat adipocytes [238].
Moreover, during adipocyte differentiation in vitro, ghrelin treatment was shown to stimulate
fat accumulation as well as mRNA expressions of adipogenic markers, like peroxisome
proliferator-activated receptor-g, adipocyte determination and differentiation-dependent factor
1 and adipose protein 2/fatty acid binding protein [237]. In addition, in brown adipocytes in
vitro ghrelin has been shown to inhibit the expression of adiponectin, which has been
implicated in the pathogenesis of insulin resistance and obesity [239], and ghrelin exerts a
receptor-mediated stimulatory effect on the leptin production of cultured rat white adipocytes
[240].
2.5.7 Gastrointestinal effects
Ghrelin stimulates gastric acid secretion and gastric motility in rodents, probably through
activation of the vagus nerve [241-243]. In humans, ghrelin accelerates gastric emptying and
the passage of food through the small intestine, and it induces the motility of the upper
gastrointestinal tract [244, 245]. The effect of ghrelin on gastric emptying may be a direct one
on the stomach itself [170] or by altering the signalling to the motor centres of the brain stem
through the vagus nerve [246, 247].
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2.5.8 Other effects
Numerous other effects have been attributed to ghrelin, including an influence on sleep [248-
250], learning and memory [251-253], stress [254], and either an antiproliferative [144, 255,
256] or positive proliferative effect on various cell lines in vitro [219, 234, 235, 239, 257-263]
2.6 Ghrelin concentration in different pathophysiological
conditions
2.6.1 Obesity
Both circulating total and acylated ghrelin levels have been shown to be reduced in obesity
[61, 71, 75, 264]. However, one study has shown higher acylated ghrelin in obese and
otherwise healthy subjects compared to non-obese healthy subjects [124].
In obesity, postprandial plasma ghrelin suppression is reduced compared to normal-
weight controls [265], while acylated plasma ghrelin does not change postprandially [266]. It
is thought that ghrelin is linked to excessive food intake in two ways. Firstly, the lesser
postprandial reduction in ghrelin levels may directly increase the length of time for which the
subject feels hungry. Secondly, as a consequence of the elevated ghrelin levels, the speed of
gastric emptying may not be reduced, and the resulting feeling of satiety not elicited. Without
these feelings of satiety, obese individuals eat more than they need, and thus gain weight
[173].
2.6.2 Effect of weight loss on ghrelin concentration
2.6.2.1 Diet-induced weight loss
So far, the majority of studies have investigated total ghrelin levels in diet-induced and
combined exercise/diet weight loss studies. A detailed summary is shown in Table 2. The
studies are very diverse, with different interventions, intervention periods, number and age of
participants, as well as inclusion criteria. Previous studies have shown either an increase in
ghrelin concentrations in obese subjects [267-273], or no change in either overweight healthy
adults [274] or obese children [275, 276], in response to diet-induced weight loss. However,
during weight maintenance after weight loss, ghrelin levels decreased back to the same levels
observed before weight loss [277]. Even an initial decrease along with weight loss and
subsequent increase in plasma ghrelin has been reported [278]. Weight loss was also shown to
increase ghrelin levels in normal-weight individuals [279].
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2.6.2.2 Exercise-induced weight loss
Few studies have been conducted to investigate the exclusive effect of weight loss through
exercise on plasma ghrelin levels, showing either an increase [280, 281] or no change [282].
Table 3 shows all studies conducted so far on this topic.
2.6.2.3 Bariatric surgery
The effect of bariatric surgery on circulating ghrelin levels has been studied intensively but
not yet clarified. Bariatric surgery involves drastic changes in gastrointestinal anatomy and
physiology and different methods can have different effects.
Ghrelin levels decrease after the Roux-en-Y gastric bypass (RYGBP) operation despite
massive weight loss, as shown by many studies [267, 283, 284]. However, other studies
suggest that RYGBP affects ghrelin concentration not directly but through the changes in
BMI with an increase in ghrelin in those subjects with substantial weight loss [285-287].
Following vertical banded gastroplasty or adjustable gastric banding, most studies agree that
fasting ghrelin levels either increase [284, 288, 289] or do not change [290]. An increase in
ghrelin levels was found after biliopancreatic diversion [284, 291, 292].
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2.6.3 Type 2 diabetes mellitus
Low ghrelin levels are associated with type 2 diabetes [76, 301]. Among patients with type 2
diabetes, fasting ghrelin levels are lower in obese subjects and higher in lean persons than in
normal-weight patients with type 2 diabetes [71, 76], with the same finding being observed
for acylated ghrelin levels [111]. Circulating ghrelin concentrations are also reduced in the
healthy offspring of type 2 diabetic patients [302].
2.6.4 Insulin resistance and metabolic syndrome
Individuals with the metabolic syndrome have lower ghrelin concentration compared to
normal-weight subjects [303-306]. Lower ghrelin concentrations have also been shown to
associate with a higher prevalence of the metabolic syndrome, with progressively lower levels
being found as the number of components of the metabolic syndrome is increased [127, 304].
This may most likely be explained by higher BMI in subjects with lower ghrelin levels, since
adiposity also influences other features of the metabolic syndrome [127, 304]. In fact, it was
shown that plasma total ghrelin as well as des-acyl ghrelin is lower in obese patients with
metabolic syndrome compared to non-obese counterparts, though acylated ghrelin was
comparable in both groups [124] or only lower in obese but not in morbidly obese compared
to normal-weight persons [306].
Among obese subjects, plasma ghrelin levels have been shown to be lower in insulin-
resistant than in insulin-sensitive persons [307], but neither total ghrelin, nor acylated or des-
acyl ghrelin separately differ between insulin sensitive and insulin resistant persons [105].
Among overweight and obese patients, the ratio of acyl/des-acyl ghrelin is lower in insulin-
sensitive than in insulin-resistant subjects [105].
A study comparing metabolically obese but normal-weight women with healthy, normal
women showed no difference between plasma total ghrelin levels for these two groups [308],
suggesting that obesity alone does not affect ghrelin levels, but rather metabolic disturbances
have an independent effect.
2.6.5 Hypertension
Low plasma ghrelin levels are associated with hypertension [76] and inversely correlated with
elevated blood pressure (BP) in different study populations [76, 309, 310]. Acylated ghrelin
levels are also negatively correlated with systolic BP [125]. Pregnant women with pregnancy-
induced hypertension, however, had higher ghrelin levels than normal pregnant women [309].
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2.6.6 Chronic conditions with negative energy balance
Anorexia nervosa is a syndrome seen in young women characterized by a combination of
weight loss, amenorrhea, and behavioural changes. Circulating ghrelin levels in patients with
anorexia nervosa are significantly elevated outside of the normal range as compared to
constitutionally thin controls [311] and fall back to within the normal range upon weight gain
by renutrition [34, 71, 82, 312, 313]. It was found that when comparing patients with anorexia
nervosa to constitutionally thin but healthy controls, the ghrelin infusions had no significant
effect on appetite [314]. This suggests a certain level of ghrelin resistance in anorexia nervosa
which could be the result of down-regulation of GHSR expression due to chronically high
levels of circulating ghrelin [173]. In bulimia nervosa, an eating disorder characterised by
habitual abnormal binge eating behaviour, higher ghrelin levels were found compared to
BMI-matched normal subjects [315, 316].
Circulating ghrelin levels are also elevated in cachexia associated with chronic heart
failure [317] or cancer [318], and administration of ghrelin has been suggested as a new
therapeutic strategy for the treatment of cachexia [319].
2.7 Animal models of ghrelin or ghrelin receptor deficiency
Knocking out the activity of a gene provides powerful information for studying the biological
function of gene products. Table 4 shows a summary of the results from studies investigating
transgenic and knockout models for ghrelin and GHSR. The global deletion of the GHRL
gene in mice results in a normal energy balance, food intake and adiposity on a standard diet
[176, 320-322]. These findings were surprising and lead to the interpretation that endogenous
ghrelin may not be of crucial relevance for physiological energy homeostasis. Others have
attributed the lack of a metabolic phenotype to compensatory processes during early
developmental phases or the presumably redundant multiplicity of pathways controlling
energy balance. Furthermore, some studies have suggested that the GHSR 1a exhibits basal
constitutive activity [152, 323] and thus could still provide possible residual signalling in
ghrelin target cells, even in the absence of the primary ligand in mice with targeted disruption
of the GHRL gene [153]. However, chronic exposure of ghrelin-deficient mice to a high-fat
diet resulted in a reduction in weight gain and increased use of fat as fuel [176, 321]. When
ghrelin deficiency was induced in adult animals, reduced food intake, reduced fat storage and
weight loss were observed [324, 325]. This suggests that ghrelin is an important player in the
field of energy homeostasis and appetite regulation, as part of a bigger network of regulatory
molecules, which can only compensate for its loss if this occurs early in development [173].
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Table 4. Animal models for ghrelin and GHSR (modified from Higgins et al, 2007 [173])
Ghrelin Embryonic/Adult Finding/phenotype compared to WT littermates Reference
Embryonic ghrelin KO No detected difference as compared to WT [320]
Embryonic ghrelin KO KO animals on a high-fat diet showed preferential
use of fat as a metabolic substrate
[176]
Embryonic ghrelin KO Males on high-fat diet showed less weight gain and
higher locomotor activity
[321]
Embryonic ghrelin KO Young animals showed lower RQ and higher heat
production
[326]
Embryonic ghrelin KO Normal body weight and feeding pattern [327]
Embryonic ghrelin KO Normal feeding behaviour; increase in locomotor
activity
[328]
Transgenic mice overexpressing
des-acyl ghrelin
Lower body weight and fat mass with decreased
food intake and gastric emptying rate
[177]
Transgenic mice overexpressing
des-acyl ghrelin
Small phenotype, lower IGF-1 levels [329]
Transgenic mice overexpressing
ghrelin
Normal size animal (no difference in food intake,
body growth, body weights, and fat depots
compared to WT). No desensitisation of the
orexigenic effect of exogenous ghrelin.
Desensitization of epididymal fat pads.
[330]
Embryonic ghrelin/leptin double KO Obesity and hyperphagia shown, but with
improved insulin sensitivity
[331]
Congenic adult ghrelin KO Lower glucose and insulin levels [332]
Adult (given synthetic
oligonucleotides to neutralise effects
of ghrelin)
Weight loss occurred in diet-induced obese mice [324]
Adult (immunisation against ghrelin) Weight loss and reduced food intake in pigs [325]
GHSR Embryonic/Adult Finding/phenotype compared to WT littermates Reference
Embryonic GHSR KO Lower body weight and IGF-1 levels [148]
Embryonic GHSR KO Reduced food intake and weight gain on high-fat
diet, increased fat burning
[322]
Embryonic GHSR KO Normal feeding behaviour [328]
Embryonic (given antisense GHSR
mRNA, which selectively attenuates
GHSR protein expression in the ARC)
Lower body weight and less adipose tissue,
reduced food intake, abolition of the stimulatory
effect of GHS on feeding
[333]
Adult (given GHSR antagonist
(D-Lys-3)-GHRP-6)
Reduced food intake and weight gain on high-fat
diet, increased fat burning
[334]
Congenic adult GHSR KO Lower body, increased insulin sensitivity [332]
Ghrelin
and
GHSR
Embryonic/Adult Finding/phenotype compared to WT littermates Reference
Embryonic ghrelin/GHSR double KO Lower body weight, decreased fat mass; normal
feeding behaviour; increased energy expenditure
[328]
WT, wild type; KO, knockout; RQ, respiratory quotient; IGF-1, insulin-like growth factor 1; ARC, arcuate
nucleus of the hypothalamus; GHS, growth hormone secretagogue
Similar to ghrelin-deficient mice, the appearance of GHSR-deficient mice is not
dramatically different from that of their wild-type littermates [148]. However, the body
weights of mature GHSR-null mice are modestly reduced compared to wild-type littermates,
which is consistent with ghrelin’s property as an amplifier of GH pulsatility [148]. In a model
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selectively attenuating GHSR protein expression in the ARC, transgenic rats had lower body
weight and less adipose tissue than did control rats [333], which is in agreement with the role
of ghrelin and its receptor in the regulation of GH secretion, food intake, and adiposity. On a
high-fat diet, GHSR-deficient mice showed reduced food intake and weight gain and utilized
fat in preference to other metabolic fuels [322, 334]. When a high-fat diet was induced in
adult ghrelin- or GHSR-deficient mice, they were not protected from weight gain, suggesting
that as animals reach adulthood, they develop compensatory pathways to adjust for the loss of
a ghrelin/GHSR signal [332].
Simultaneous knockout of the GHRL and the GHSR genes leads to changes in energy
balance, which are not observed in mice deficient for either the ligand or the receptor alone on
normal standard chow [328]. It was therefore speculated that either ghrelin may also act
through an additional, as yet unknown, receptor, or that there exists another ghrelin-like
ligand [328].
2.8 Genetic variations in the GHRL and GHSR genes in humans
Polymorphisms in the human GHRL gene and the 5’-flanking region have been intensively
studied. The most studied SNP is the Leu72Met located in exon 3, which changes the amino
acid sequence from Leucine to Methionine at position 72 in the prepro-ghrelin protein. The
Arg51Gln SNP of GHRL is located in exon 3 within the last codon of the mature ghrelin
protein and disrupts the recognition site of the endoprotease, leading to proteolytic cleavage
of the carboxy-terminal 66 amino acids to produce mature ghrelin [335]. Table 5 shows NCBI
RefSNP accession ID’s (rs numbers) [336] corresponding to the name of SNPs based on their
position and their location in GHRL. Table 6 summarizes most genetic association studies
dealing with SNPs in the GHRL gene to date. Nonetheless, reports on SNPs in the GHSR gene
are sparse. All studies carried out so far are described in Table 7.
Table 5. GHRL SNPs and their corresponding NCBI RefSNP accession IDs (rs-numbers),
position and SNP location.
Rs number Position SNP location Rs number Position SNP location
rs1629816 -4427G>A1 5’-region rs34911341 Arg51Gln2 Exon 3
rs10490815 -3281A>G1 5’-region rs696217 Leu72Met2 Exon 3
rs27498 -2157G>A1 5’-region rs2075356 +3056T>C1 Intron 3
rs3755777 -1500C>G1 5’-region rs4684677 Gln90Leu2 Exon 4
rs26311 -1062G>C1 5’-region rs35684 +5179A>G1 3’-region
rs26312 -994C>T1 5’-region rs171407 +5696A>G1 3’-region
rs27647 -604G/A1 5’-region rs171336 +6115G>T1 3’-region
rs26802 -501A/C1 5’-region rs2072578 +9344G>A1 3’-region
novel -473G/A1 5’-region
1 number denotes the nucleotide position either upstream (-) or downstream (+) of the translation initiation site;
2 number denotes amino acid position
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2.8.1 Association with obesity
Several studies have found associations between GHRL SNPs and obesity or related traits,
although the results are contradictory. The Met72 allele of GHRL was shown to be associated
with earlier age at onset of obesity and higher BMI [264, 337-340], whereas the opposite has
also been reported [335, 341]. The -501A>C SNP in GHRL promoter and the intronic
+3056T>C SNP were also associated with obesity [342, 343], although some studies have
failed to find any association between GHRL SNPs and obesity [76, 264, 339, 344-350].
Furthermore, GHRL SNPs were associated with metabolic syndrome in one study [346], but
not in another [345]. Only one study has shown an association with the haplotypes of five
GHSR SNPs and obesity [351], whereas another study could not show such a relationship
[352].
Table 6. Studies on the associations of SNPs in the GHRL gene.
SNP Risk
allele
Association Subjects Refer-
ence
Leu72Met
Arg51Gln
Met72
Gln51
Lower age of onset of self-reported obesity
Not found among normal-weight subjects
96 obese and 96 normal-weight
Swedish women
[337]
Leu72Met
Arg51Gln
Leu72
Gln51
Higher BMI, fat mass, visceral fat, total
TG and RQ; lower IGF-1 levels in Blacks
Lower frequency in Whites than in Blacks
Not observed among Blacks
784 French-Canadian subjects
(Quebec Family Study)
778 subjects (276 Blacks and 502
Whites; HERITAGE Family Study)
1442 subjects (741 from obese
registry, 701 from normal reference
population; SOS)
[335]
Leu72Met Met72 Higher BMI, earlier age of onset of
obesity, reduced first phase insulin
secretion
70 tall and obese children [338]
Gln90Leu Gln90 Higher frequency in obese children, but
also in underweight students
215 extremely obese German
children and adolescents
93 normal-weight students
134 underweight students
44 normal-weight adults
[353]
Leu72Met Met72 Lower serum creatinine and lipoprotein a
levels
258 Finnish Caucasians with T2D
and 522 controls
[354]
Arg51Gln Gln51 Risk factor for hypertension and T2D,
predictor of 2-h plasma glucose in OGTT;
lower IGF-1 and higher IGFBP-1
concentrations
in normotensives: lower AUC insulin
519 hypertensive and 526
normotensive Finnish Caucasians
[355]
Arg51Gln
Leu72Met
Both: no association 519 hypertensive and 526
normotensive Finnish Caucasians
[76]
Arg51Gln
Met72Leu Met72
No association
Earlier onset of obesity
300 obese and 200 lean Italian
children and adolescents
[339]
Leu72Met
Gln90Leu
Arg51Gln
Met72 In obese/overweight: greater neonatal
weight-for-age, earlier age at onset of
obesity, greater IGF-1 concentration.
No association with obesity phenotypes
No association with obesity phenotypes
81 obese or overweight and 96
normal-weight Italian children and
adolescents and 72 normal-weight
young adults
[264]
-4427G>A
Leu72Met
+5179A>G
+9344G>A
G Diffuse large cell lymphoma
All three: no associations with BMI
684 healthy controls and 308 North
American subjects with non-
Hodgkin Lymphoma
[344]
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Table 6. Continued
SNP Risk
allele
Association Subjects Refer-
ence
Leu72Met No difference between genotype and allele
frequency between healthy and subjects
with MetS, no association with related
quantitative traits
2413 Danish Caucasian subjects (of
which 279 with MetS)
[345]
Arg51Gln
Leu72Met
Gln90Leu
Gln51
Met72
Less MetS
Higher fasting glucose, lower HDL
cholesterol, higher TG; more MetS
No significant associations
All three: no association with BMI, waist,
T2D
856 Old Order Amish from US [346]
Arg51Gln
Leu72Met
Gln90Leu
All three: no association with obesity- or
T2D-related traits
234 juvenile-onset obese and 323
lean men, 557 T2D and 233 glucose
tolerant subjects
[347]
Leu72Met Met72 More depressed and anxious in patients
with MetDep; no association with MetDep
118 Koreans with methamphetamine
dependence (MetDep), 144 controls
[356]
Leu72Met No association with obesity 222 obese Korean children [348]
-1500C>G
-1062G>C
-994C>T
Leu72Met
C Lower HDL cholesterol.
All four: no association with T2D
760 T2D and 641 non-diabetic
Koreans
[14]
Leu72Met Met72 Lower allele frequency and lower total
cholesterol levels in patients with diabetic
nephropathy with renal dysfunction
138 subjects with diabetic
nephropathy, 69 diabetics without
nephropathy
[357]
Leu72Met Met72 Lower creatinine levels in diabetic group,
no association with T2D
206 T2D, 80 controls [358]
-501A>C A Higher BMI 1045 Finnish subjects from the Oulu
Project Elucidating Risk for
Atherosclerosis (OPERA) study
[343]
Leu72Met No association with weight loss 771 obese Caucasian Europeans [349]
Leu72Met Met72 Higher allele frequency in higher BMI
group than in normal-weight group
Higher BMI, waist circumference and
change in body weight from age 18
No difference in allele frequency between
diabetics and non-diabetics
2238 middle-aged and older
Japanese people
[340]
Leu72Met Leu72 Higher BMI in CAD patients;
no association with CAD
no association with hypertension, T2D or
dyslipidaemia
317 Chinese CAD patients, 323
controls
[341]
Leu72Met
+3056T>C
Met72
C
Higher scores on Drive for Thinness-Body
Dissatisfaction subscale
Higher weight, BMI, fat mass, waist
circumference, sum of skinfold
thicknesses, self-reported past min and
max BMIs and lower HDL cholesterol
264 Japanese women [342]
-604C>T
Leu72Met
Gln90Leu
Haplotypes:
-604G/Leu72
versus
-604A/Leu72
-604G/Met72
C
Leu72
Higher fasting insulin and HOMA-IR, but
only in Leu72 subjects
Higher TG, fasting insulin and HOMA-IR
No associations
-604G/Leu72 higher insulin and HOMA-
IR than other haplotypes
1420 Caucasian subjects (500
normal-weight, 920
overweight/obese)
[359]
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Table 6. Continued
SNP Risk
allele
Association Subjects Refer-
ence
Arg51Gln
Leu72Met
Genotype
combination
Gln51 Gln51 allele carriers developed higher
cholesterol levels over time
No association
Subjects with Gln51 and/or Met72 allele
lost body weight faster than patients with
Arg51Arg/Leu72Leu (no weight loss)
210 haemodialysed patients,
prospectively followed up for 15
months
[360]
Arg51Gln
Leu72Met
Gln90Leu
All three: no associations 198 children with short stature (117
with GH-deficiency and 81 with
idiopathic short stature); 125 age
and gender-matched healthy
children as controls
[361]
rs10490815
rs27498
rs3755777
-604T>C
-501T>G
Leu72Met
+3056A>G
Gln90Leu
rs35684
rs171407
rs171336
A
G
A
G
G
No associations
Lower height
Associated with 5% lower IGF-1 levels;
lower height
No associations
No associations
No associations
No associations
No associations
No associations
Higher BMI; lower height;
Higher breast cancer risk
Lower height
1359 breast cancer cases and 2389
matched controls participating in the
EPIC study
[350]
TG, triglycerides; RQ, respiratory quotient; IGF-1, insulin-like growth factor 1; T2D, type 2 diabetes mellitus;
IGFBP-1, insulin-like growth factor binding protein 1; AUC, area under the curve; MetS, metabolic syndrome;
HOMA-IR, homeostasis model assessment for insulin resistance; MetDep, methamphetamine dependence; CAD,
coronary artery disease; GH, growth hormone; EPIC, European Prospective Investigation into Cancer and
Nutrition
2.8.2 Association with type 2 diabetes
The Gln51 allele of Arg51Gln in GHRL was reported to be a risk factor for type 2 diabetes
[355] and the Leu72Met SNP was associated with type 2 diabetes-related phenotypes in some
studies [346, 359], while others have reported negative results [14, 340, 341, 346, 358]. Only
one report has shown an association between GHSR SNPs and insulin metabolism [362].
2.8.3 Association with hypertension
The Gln51 allele of the Arg51Gln SNP in GHRL has been found to be a risk factor for
hypertension [355], though the data concerning the Leu72Met SNP are inconsistent [76, 335,
341, 354]. GHSR SNPs have not been associated with hypertension.
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Table 7. Studies on the associations of SNPs in the GHSR gene.
SNP Risk
allele
Association Subjects Refer-
ence
rs572169
rs495225 T
No association
Initially higher allele and genotype
frequency in obese compared to
underweight; could not be replicated
746 obese German children and
adolescents, 232 underweight, 96
normal-weight students, 43
children with short normal stature
[352]
rs2232165
rs495225
rs2232169
rs572169
rs4988509
CC
GG
No associations
Highest AUCIN values, lowest IGFBP-
1 plasma levels
No associations
Highest AUCIN values
No associations
Finnish hypertensive subjects, 96
with high and 96 with low total
IGF-1 plasma concentrations
[362]
rs582780
rs544672
rs578015
rs509035
rs572169
rs519384
rs512692
rs490683
rs1523324
rs1992869
MA
MA
MA
MA
MA
No association with obesity
No association with obesity
No association with obesity
Haplotype with 5 minor alleles (SNPs
italic) associated with obesity; those
5 SNPs are also individually associated
with obesity
No association with obesity
No association with obesity
1095 Caucasians (from families),
1418 subjects from general
population
[351]
rs495225 C Higher genotype frequency in bulimia
nervosa
228 Japanese patients with eating
disorders, 284 controls
[363]
rs582780
rs544672
rs578015
rs509035
rs572169
rs519384
rs512692
rs490683
rs1523324
rs1992869
MA
MA
MA
MA
MA
No association with LVH
No association with LVH
No association with LVH
Association with LVH
Association with LVH
Association with LVH
Association with LVH
Association with LVH
No association with LVH
No association with LVH
1230 Germans [364]
rs579015
rs509035
rs572169
rs519384
rs512692
rs490683
rs1523324
MA
MA
MA
MA
MA
No association with MI or CAD
Higher risk of MI or CAD
Higher risk of MI or CAD
Higher risk of MI or CAD
Higher risk of MI or CAD
Higher risk of MI or CAD
No association with MI or CAD
1390 Germans with myocardial
infarction (MI), 940 with MI or
coronary artery disease (CAD),
1418 German controls, 638
controls (non-affected siblings)
[365]
rs2948694
rs495225
rs572169
rs2922126
C
A
No associations
No associations
Lower height
Higher BMI
1359 breast cancer cases and 2389
matched controls participating in
the EPIC study
[350]
IGF-1, insulin-like growth factor 1; AUCIN, area under the insulin curve; IGFBP-1, insulin-like growth factor
binding protein 1; MA, minor allele; LVH, left ventricular hypertrophy; MI, myocardial infarction; CAD,
coronary artery disease; EPIC, European Prospective Investigation into Cancer and Nutrition. SNPs belonging to
a haplotype are in italic font.
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2.8.4 Association with ghrelin plasma concentration
Only a few studies have investigated the association between ghrelin polymorphisms and
plasma ghrelin levels and have created inconsistent results (Table 8).
Table 8. Studies on the associations between polymorphisms in the GHRL gene with plasma
ghrelin concentrations.
SNP Association with plasma ghrelin
concentration
Total, acyl-
or des-acyl
ghrelin, ratio
Subjects Refer-
ence
Arg51Gln
Leu72Met
Arg51Gln (n=6) lower than Arg51Arg
subjects (n=14)
No sign. difference between 3
genotypes (Met72Met (n=4) tended to
have highest levels)
Total ghrelin 784 subjects (Quebec Family
Study)
[335]
Arg51Gln
Leu72Met
Gln51 allele carriers lower
concentrations
Only in hypertensive group:
Leu72Leu higher than Leu72Met
persons, but Met72Met highest levels
Total ghrelin 519 hypertensive and 526
normotensive Finnish
Caucasians
[76]
Leu72Met
Gln90Leu
Arg51Gln
All three: no associations Total and
acylated
ghrelin,
acyl/total ratio
81 obese or overweight and 96
normal-weight Italian children
and adolescents and 72 normal-
weight young adults
[264]
-501A>C Genotype distribution different
between the groups (AA genotype in
low ghrelin group and C allele carriers
in high ghrelin group more common)
Total ghrelin 50 Finnish patients with low and
50 with high plasma ghrelin
concentrations
[343]
-501A>C No difference between 3 genotypes Total ghrelin 1045 Finnish subjects from the
Oulu Project Elucidating Risk
for Atherosclerosis (OPERA)
study
[343]
Leu72Met
+3056T>C
Met72 allele carriers higher acylated
ghrelin concentration
C allele carriers higher acylated
ghrelin concentration
Acylated and
des-acyl
ghrelin,
acyl/des-acyl
ratio
264 Japanese women [342]
-604C>T
Gln90Leu
Leu72Met
Haplotypes:
-604G/Leu72
versus
-604A/Leu72
-604G/Met72
No association
No association
Leu72Leu < Leu72Met < Met72Met
-604G/Leu72 lower ghrelin levels
than other haplotypes
Total ghrelin 1420 Caucasian subjects (500
normal-weight, 920 overweight
or obese), subpopulation 300
overweight or obese
[359]
Arg51Gln
Leu72Met
Gln90Leu
All three: no association Total ghrelin 80 children with GH-deficiency,
57 with idiopathic short stature
and 35 healthy controls
[361]
GH, growth hormone
51
3 Aims of the study
The aim of the work presented in this thesis was to study the role of ghrelin and the ghrelin
receptor in the development of obesity and impaired glucose metabolism. The studies
conducted within the scope of this thesis are mostly based on data collected in large
intervention projects.
Consequently, the specific aims of this work were to:
· Study the associations between polymorphisms in the GHRL gene and the incidence of
type 2 diabetes (Study I), obesity (additional results) or hypertension (Study II) in
persons with impaired glucose tolerance participating in the Finnish Diabetes
Prevention Study (DPS).
· Study the associations between SNPs in the GHSR gene and obesity and type 2
diabetes-related phenotypes in the Finnish DPS (Study III).
· Conduct a promoter analysis of the GHSR gene to investigate SNPs disrupting
putative transcription factor binding sites and subsequently test their potential
functionality in vitro (Study III).
· Examine the expression of ghrelin and ghrelin receptors in peripheral blood
mononuclear cells (PBMCs) and subcutaneous adipose tissue in individuals with
features of metabolic syndrome in the Genobin study (Study IV).
· Evaluate the effects of weight reduction or exercise intervention on plasma ghrelin
concentrations, as well as on ghrelin expression in PBMCs and adipose tissue from
participants in the Genobin study (Study IV).
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4 Subjects and Methods
4.1 Study populations and study designs
4.1.1 The Finnish Diabetes Prevention Study (Studies I-III)
The Finnish Diabetes Prevention Study (DPS) is a multicentre study with five participating
centres in Finland, located in Helsinki, Kuopio, Oulu, Tampere and Turku [366]. The main
aim of the DPS was to assess the efficacy of an intensive and individually designed diet and
exercise program to prevent or delay the onset of type 2 diabetes in Finnish subjects with
IGT.
Overweight subjects (BMI over 25 kg/m2) aged 40 to 64 years at randomization and who
had IGT were eligible for the study. Impaired glucose tolerance (IGT) was defined according
to the WHO 1985 criteria [367], i.e., as a plasma glucose concentration of 7.8-11.0 mmol/L
two hours after the oral administration of 75 g of glucose with a non-diabetic fasting plasma
glucose concentration (<7.8 mmol/L). After the first screening OGTT, a second OGTT was
carried out in subjects with IGT, and the mean of the two 2-hour glucose concentrations was
used as the criterion for inclusion in the study. A total of 522 subjects were randomly
assigned to one of the two treatment groups: the intensive diet and exercise counselling group
(n=265) or the control group (n=257). The subjects in the control group were given general
oral and written information about diet and exercise at baseline and at subsequent annual
visits, but were offered no specific individualized programs. The subjects in the intervention
group were given detailed advice about how to achieve the goals of the intervention [366]. At
baseline and at each annual visit, all study subjects completed a medical-history questionnaire
and underwent a physical examination that included anthropometric and BP measurements, as
well as an OGTT. The most intensive intervention was carried out during the first year of the
study, and the study was terminated after a mean follow-up of 3.2 years when the risk of
diabetes had been reduced by 58% in the intervention group compared with the control group
[368]. However, participants were thereafter invited to take part in the extended follow-up
period, and the follow-up of the diabetes incidence is still ongoing.
4.1.2 The Genetics of obesity and insulin resistance study (Study IV)
Originally, the Genetics of Obesity and Insulin resistance (Genobin) Study included
75 overweight or obese (BMI range 28 to 40 kg/m2) men and women aged 40 to 70 years with
impaired fasting glucose (IFG) or IGT, and at least two other features of metabolic syndrome
according to the Adult Treatment Panel III criteria as modified by the American Heart
Association [369, 370]. Subjects were randomized into one of the following groups: a weight
reduction group (n=28), aerobic exercise training group (n=15), resistance exercise training
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group (n=14) or control group (n=18). Subjects were matched for age, gender and the status
of glucose metabolism. In addition, 11 normal-weight subjects (mean age 48±9 years, mean
BMI 23.7±1.9 kg/m2) were recruited. The weight-reduction group underwent a 12-week
intensive weight-reduction period followed by a weight-maintenance period during study
weeks 12-33 [369]. Subjects were asked to maintain their habitual level of physical exercise
unchanged. For subjects in the exercise training groups, aerobic and resistance training group,
respectively, the individualized and progressive training programs, which lasted for 33 weeks,
were prescribed based on measured cardiorespiratory fitness and muscular strength levels.
Muscle strength was measured using 5-repetition maximum tests, which were conducted
before every modification in the program as well as at the end of the program. Participants
also had follow-up visits once a month. The subjects in the control group were advised to
continue their normal lifestyle during the study and to keep their diet and exercise habits
unchanged.
Biochemical, anthropometric and BP measurements were performed at baseline, week 12
and at the end of the study at week 33. Frequently sampled intravenous glucose tolerance test
(FSIGT) and adipose tissue biopsy were performed at baseline and at the end of the study.
4.1.3 Approval of the Ethics Committee
The study protocol was approved by the ethics committee of the National Public Health
Institute in Helsinki, Finland (Studies I-III). The Ethics Committee of the District Hospital
Region of Northern Savo and Kuopio University Hospital approved the study plan, and the
intervention was performed in accordance with the standards of the Helsinki Declaration
(Study IV). Written informed consent was obtained from all study subjects.
4.2 Methods
4.2.1 Clinical and biochemical examinations
4.2.1.1 Anthropometric measurements
Weight and height were measured in light clothing and BMI was calculated in all studies by
dividing weight (kg) by height (m) squared. Waist circumference was measured mid-way
between the lowest rib and iliac crest. BP was measured by trained study nurses using a
standard sphygmomanometer twice on the right arm after 10 min of rest with the subject in a
sitting position. The mean of systolic and diastolic BP was calculated from the two
measurements obtained. Hypertension was defined as the mean systolic BP of ³140 mmHg or
diastolic BP of ³90 mmHg, or taking antihypertensive medication [371, 372].
Studies I-III. Weight change was calculated as the difference in weight between the baseline
and three years. For those developing diabetes, weight change was calculated from the
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baseline value to the last weight measurement available, which varied from one to three years
depending on the date of diagnosis of type 2 diabetes.
Study IV. Relative weight change was calculated as:
(weight at week 33 – weight at baseline) / weight at baseline x 100.
4.2.1.2 Laboratory measurements
A 2-hour OGTT with a glucose dose of 75 g after a 12-hour overnight fast was carried out to
determine glucose tolerance. Blood samples for plasma glucose and serum insulin
concentrations were drawn at 0, 30, and 120 min.
Studies I-III. Plasma glucose was measured locally by standard methods, and the
measurements were standardised by the central laboratory in Helsinki. Serum insulin was
determined with a radioimmunoassay (RIA) (Pharmacia, Uppsala, Sweden). Serum total
cholesterol, HDL cholesterol and TG were determined using an enzymatic assay method
(CHOD-PAP, Boehringer Mannheim, Germany, Monotest). LDL cholesterol was calculated
using the Friedewald formula: Total cholesterol – (HDL cholesterol + TG / 2.2), and applied
only when TG levels were below 4.5 mmol/L [373]. For subjects with TG levels
>4.5 mmol/L, no LDL cholesterol calculations were performed. The homeostasis model
assessment for insulin resistance (HOMA-IR) was calculated using the following formula:
fasting plasma glucose (mmol/L) x fasting serum insulin (mU/L) / 22.5 [374].
Study IV. Biochemical analyses were performed using routine methods at the Clinical
Laboratory Centre of the Kuopio University Hospital and at the Clinical Unit of the
University of Kuopio. Plasma glucose concentration was analysed by the hexokinase method
(Thermo Clinical Labsystems, Vantaa, Finland), and insulin was determined by the
chemiluminescence sandwich method (ACS, Bayer A/S, USA). Lipoproteins were separated
by ultracentrifugation (Beckman Optima L-90K) preceding enzymatic methods (Roche
Diagnostics, Mannheim, Germany) on Kone Pro Clinical Chemistry Analyser (Thermo
Clinical Labsystems, Konelab, Espoo, Finland) to analyse cholesterol, TG and HDL-
cholesterol. Serum free fatty acids were measured with a turbidometric analyser (CV% 1.5)
(Kone Ltd, Espoo, Finland). Commercial RIA kits were used for the analysis of serum leptin
and plasma total ghrelin (Linco Research Inc., St. Louis, MO, USA). Plasma TNF-?, IL-6 and
IL1-? concentrations were measured by solid phase enzyme-linked immunosorbent assay
(ELISA) (Quantikine, R&D Systems, Minneapolis, MN, USA). High-sensitivity C-reactive
protein (hsCRP) was determined using the Immage Immunochemistry System (Immulite 2000
DPC, Los Angeles, LA, USA).
The FSIGT was performed according to the Minimal Model method by administrating
300 mg/kg body weight glucose through a catheter inserted into an antecubital vein as a 50%
solution. Plasma glucose and serum insulin concentrations were followed for three hours,
collecting altogether 25 blood samples. During the first 10 minutes, blood samples were
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drawn every two minutes and just before the 20 min insulin bolus (0.03 U/kg body weight).
The results were calculated with MINMOD Millennium software [375] as glucose
effectiveness (SG), insulin sensitivity (SI) and acute phase insulin response (AIR) using the
area of insulin concentration above the baseline during 0-10 minutes.
4.2.2 Selection of single nucleotide polymorphisms
4.2.2.1 GHRL polymorphisms
Originally, genetic variations in the GHRL gene were determined by direct sequencing of the
coding region and the proximal promoter area (1 kb upstream of the translation start site) in
35 massively obese Finnish subjects [376]. Six SNPs were detected in this study population
and subsequently genotyped in other study populations: three SNPs in the 5’-region: -604G/A
(rs27647), -501A/C (rs26802) and the novel variation -473G/A, and three SNPs in the coding
region: Arg51Gln (rs34911341), Leu72Met (rs696217) and Gln90Leu (rs4684677) (Figure 4).
Figure 4. Polymorphic sites in the 5’-region and the coding sequence of GHRL (modified from
Study II [377]). Black boxes, untranslated region; dark grey box, signal peptide; light grey boxes,
mature ghrelin peptide; white boxes, cleaved from mature form.
4.2.2.2 GHSR polymorphisms
For selection of GHSR SNPs for genotyping, the HapMap [378], NCBI [336] and Ensembl
[379] databases and previously published reports were used. Publicly available genotyping
data for the genomic regions of interest were examined with Haploview software [380].
Linkage disequilibrium (LD) statistics were calculated and the haplotype blocks visualized.
SNPs were either selected manually or using Tagger software
(http://www.broad.mit.edu/mpg/tagger/server.html) [381].
Originally, six tag SNPs from two haploblocks covering 15 kb of the gene with three
SNPs in the 5’ end of the gene (rs474225, rs490683 (alternative name in HapMap rs863441),
and rs9819506), one in the coding region in exon 1 leading to a synonymous amino acid
1 kb
Gln90Leu-604G/A
-501A/C
-473G/A Leu72Met
Arg51Gln
Exon 1 2 3 4 5
5’
GHRL: Chromosome 3p25-26
3’
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substitution (rs495225), one in the intron (rs509035) and one in the 3’ end of the GHSR gene
(rs565105) were selected (Figure 5). In addition, all SNPs in haploblock 1 in the 5’-regulatory
region (spanning over 17 kb, chr 3: 173648897-17365897) available in the HapMap database
and located in putative TF-binding sites were tested in gelshift experiments. SNPs showing
differential protein binding were genotyped additionally (rs6772676).
Figure 5. Schematic representation of the human GHSR gene indicating the locations of analysed
SNPs belonging to two haploblocks (Study III).
 SNPs genotyped in DPS population
# SNPs from HapMap database in TF-binding sites and tested in gelshift assays
4.2.3 DNA analysis
4.2.3.1 DNA extraction
Genomic DNA was prepared from peripheral blood leukocytes by the salting out method
[382].
4.2.3.2 Restriction fragment length polymorphism analysis
Polymerase chain reactions (PCR) were performed with thermo cyclers (GeneAmp PCR
system 2700, Applied Biosystems, Foster City, CA, USA). The six SNPs in the GHRL gene
were detected by PCR based-restriction fragment length polymorphism analysis (PCR-RFLP).
The genomic DNA was amplified by PCR, followed by digestion with specific restriction
enzymes (Fermentas, Tamro Medlab OY, Vantaa, Finland) for three hours. The primers and
restriction enzymes used are presented in Table 9. The fragments were separated on an
agarose gel and visualized under ultraviolet light after staining with ethidium bromide
(Figure 6). Approximately 10% of the samples were repeated.
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Table 9. Primers used for amplification of regions where SNPs of interest in the GHRL gene
are located and respective restriction enzymes used for digestion of PCR fragments
SNP Primer 5’ to 3’ Restriction enzyme
(Temperature)
-604G/A F: CACAGCAACAAAGCTGCACC
R: AAGTCCAGCCAGAGCATGCC
DraI (37°C)
-501A/C F: AGAACAAACGCCAGTCATCC
R: GTCTTCCAGCCAGACAGTCC
MwoI (37°C)
-473G/A same as for -501A/C FokI (55°C)
Arg51Gln F: GCTGGGCTCCTACCTGAGC
R: GGACCCTGTTCACTGCCAC
SacI (37°C)
Leu72Met same as for Arg51Gln BsrI (65°C)
Gln90Leu F: GAGGTGTCACTCAGCAGTCC
R: TCTTCTTCTTCAGGGCCTGGCTGTGCTGCTAGTAC
(mismatch nucleotide introduced to the primer is underlined)
ScaI (37°C)
Figure 6.
PCR-RFLP analysis of the
six SNPs in the GHRL gene
and its promoter. In the gel
pictures, the first lane always
represents the wild-type
homozygotes, the second
lane the heterozygotes, and
the third lane the mutated
homozygotes. For the three
SNPs in the prepro-ghrelin
protein (Arg51Gln,
Leu72Met, and Gln90Leu),
the lanes are named with
one-letter amino acid codes:
R = Arg, Q = Gln, L = Leu,
M = Met. Representative
gels are shown (adapted
from Study II [377]).
4.2.3.3 TaqMan allelic discrimination assay
Genotyping of GHSR SNPs was performed with TaqMan Allelic Discrimination Assays
(Applied Biosystems, Foster City, CA, USA). The PCR amplification was performed in a
GeneAmp PCR system 2700 (Applied Biosystems, Foster City, CA, USA) under the
following conditions: 95°C for 10 min and 40 cycles of denaturation 92°C for 15 sec and
annealing/extension 60°C for 1 min. The assay IDs from Applied Biosystems for the
corresponding SNPs used are presented in Table 10. Fluorescence was detected on an ABI
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Prism 7000 sequence detector. A subset of randomly selected samples representing 6.3% of
the study cohort was repeated.
Table 10. TaqMan genotyping assay IDs for GHSR SNPs genotyped in Study III.
NCBI SNP Reference Assay ID (Applied Biosystems)
rs6772676 C___1307047_10
rs474225 C___1079483_10
rs490683 C___2169194_10
rs9819506 C___2863288_10
rs495225 C___1079488_1
rs509035 C___2863306_10
rs565105 C___2399556_20
4.2.4 Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from Genobin study participants (Study IV)
were isolated from anticoagulated peripheral blood by density centrifugation using the
Lymphoprep® reagent (Axis-Shield, Norway) according to the manufacturer’s instructions.
Altogether, 56 samples for all three time-points were available for 24 subjects in the weight-
reduction group, 9 subjects in the resistance training group, 13 subjects in the aerobic training
group, and 10 subjects in the control group. Only those subjects from whom PBMC samples
were available at all three time-points were included in the analysis.
4.2.5 Adipose tissue biopsy
Adipose tissue samples from Genobin study participants (Study IV) were taken by syringe
from subcutaneous abdominal adipose tissue under local anaesthesia after an overnight fast to
collect 0.5-5 g of adipose tissue for adipocyte isolation and RNA extraction [369]. Adipose
tissue samples for the mRNA expression studies were washed twice with PBS and treated
with RNAlater (Ambion, Austin, TX) according to the instructions provided by the
manufacturer, and stored at -80°C until used for RNA extraction.
4.2.6 RNA isolation
Total RNA from adipose tissue from Genobin study participants (Study IV) was extracted
using the TRIzol method followed by further purification with RNeasy Mini Kit columns
according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA, and Qiagen,
Valencia, CA, USA). Total RNA from PBMCs was isolated using RNeasy Mini Kit columns
according to the manufacturer’s instructions (Qiagen, Valencia, CA, USA). The RNA
concentration and the A260/A280 ratio was measured using a NanoDrop spectrophotometer
(NanoDrop Technologies, DE, USA), with an acceptable ratio being 1.9-2.1. Integrity of the
RNA was assessed using agarose gel electrophoresis.
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4.2.7 Quantitative real time polymerase chain reaction
RNA was reverse transcribed into cDNA using High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA). Quantitative real-time PCR analyses (Study IV) were
performed with TaqMan® chemistry using ready made assays according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA); the assays used in
this study are presented in Table 11. Samples were analysed in triplets with an Applied
Biosystems 7500 Real-Time PCR System (Foster City, CA, USA). The absolute
quantification was used with a standard curve, using points of 0.5, 1.5, 6, 18 and 36 ng and a
calibrator of 6 ng of mRNA equivalent. The cDNA pool for the standard curve was created by
combining cDNA from a representative number of subjects of all three time points for PBMC
samples and from two time points for adipose tissue samples, respectively. Quantities on each
plate were first corrected by the calibrator on the plate. Quantity values were finally
normalised to the expression of the endogenous control, which was glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) for PBMCs. Cyclophilin A1 was used as the endogenous
control for human adipose tissue.
Table 11. Applied Biosystems assay IDs for studied genes.
Gene Gene ID AB assay ID
Ghrelin GHRL Hs00175082_m1
Growth hormone secretagogue receptor 1a GHSR 1a Hs01026313_m1
Growth hormone secretagogue receptor 1b GHSR 1b Hs01031463_s1
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Hs99999905_m1
Peptidylprolyl isomerase A (cyclophilin A1) PPIA Hs99999904_m1
Tumour necrosis factor (TNF-alpha) TNF Hs00174128_m1
Interleukin 1, beta IL1B Hs00174097_m1
Interleukin 6 IL6 Hs00174131_m1
4.2.8 Protein extraction
Study III: Hypothalami of three male Sprague-Dawley rats (supplier Harlan, Netherlands)
were pooled and the frozen tissue was homogenised in 0.5 ml of low salt buffer (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 50 mM KCl, 0.5 mM dithiothreitol, proteinase inhibitors)
using a rotor-stator homogeniser (ART Labortechnik, Müllheim, Germany). Cells were then
resuspended in 2-3 packed volumes of the same low salt buffer with 0.5% Nonidet P-40 and
homogenised by pipetting on ice. The nuclear pellet was subsequently resuspended in one
packed cell volume of high salt buffer (10 mM Hepes, pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, proteinase inhibitors). Extraction was
performed for 30 min on ice.
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4.2.9 Gelshift assays
Gelshift assays (Study III) were performed with 10 µg of protein of the nuclear extracts. The
proteins were incubated for 15 min in a total volume of 20 µl of binding buffer (150 mM KCl,
1 mM dithiothreitol, 25 ng/ml herring sperm DNA, 5% glycerol, 10 mM Hepes, pH 7.9).
Constant amounts (1 ng) of 32P-labeled double-stranded oligonucleotides (50,000 cpm)
containing either one of the respective SNP alleles (Table 12) were then added, and
incubation was continued for 20 min at room temperature. Protein-DNA complexes were
resolved by electrophoresis in 8% non-denaturing polyacrylamide gels (mono- to
bisacrylamide ratio 19:1) in 0.5 x TBE (45 mM Tris, 45 mM boric acid, 1 mM EDTA,
pH 8.3) for 90 min at 200 V and quantified on a FLA-3000 reader (Fuji, Tokyo, Japan) using
ScienceLab99 software (Fuji).
Table 12. Oligonucleotides used in gelshift assays (Study III).
SNP Oligo sequence 5’-3’
rs6772676 AGCCTCAACACCTGACGATTTTTCAGGG
AGCCTCAACACCTGATGATTTTTCAGGG
rs9881097 GGTTCTACCTTCCTTAGTTAAGCTTCATCC
GGTTCTACCTTCCTCAGTTAAGCTTCATCC
rs474225 GCCTTTGTTTCCCTTTCATCT
GCCTTTGCTTCCCTTTCATCT
rs490683 CCATATAAAAGAGGTCCCAGAAAGCT
CCATATAAAAGAGGTGCCAGAAAGCT
rs11918879 ACTTTTTAATAAATGATGCTGAAACAACTG
ACTTTTTAATAAATGATGTTGAAACAACTG
rs477441 ACTAAAGCCAAAAAATAATAGAACA
ACTAAAGCCACAAAATAATAGAACA
rs9819506 AGCTGGAATGCATATAAGTGACAT
AGCTGGAATACATATAAGTGACAT
rs519384 TTAAAAACTCAATTTGGGGCCG
TTAAAAACTCTATTTGGGGCCG
Nucleotides in bold denote the two alleles for the respective SNP.
4.2.10 Promoter analysis
In silico promoter analysis (Study III) of the sequences containing all GHSR SNPs in
haploblock 1 for putative TF binding sites was performed using Genomatix MatInspector
Release professional 7.4.8.2 [383]. We determined all SNPs which lie in possible TF binding
sites and consequently all TF binding sites which are disrupted by either one of each SNP
allele. We used a threshold of 0.75 for core similarity and the optimized setting for matrix
similarity.
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4.2.11 Statistical analysis
Statistical analyses were performed using SPSS software versions 11.5.1 (Studies I and
II) and 14.0 (Studies III and IV) for Windows (SPSS Inc., Chicago, IL, USA). Normal
distribution was tested using the Kolmogorow-Smirnov test with Lilliefors correction. To
normalise skewed distributions, logarithmic transformations or reciprocal transformations
were applied when needed. Homogeneity of variances was tested using Levene’s test. A
p-value of 0.05 or lower was considered statistically significant. Data are given as
means ± SD, unless otherwise stated. To correct for multiple hypothesis testing (Study III), the
false discovery rate (FDR) was calculated using Q-value 1.0 software [384]. ?0 was estimated
with the bootstrap method using a ? range from 0 to 0.9 by 0.05. The FDR for each p-value is
reported as q. LD statistics and Hardy-Weinberg disequilibrium were calculated, and
haplotype blocks were visualized using Haploview software [380].
Comparisons of continuous variables between the genotype or genotype combination
groups were evaluated with the general linear model for the univariate analysis of variance
(ANOVA) for normally distributed variables, and the nonparametric Mann-Whitney or
Kruskal-Wallis tests for non-normally distributed variables. Categorical variables were
compared with a c2 test or a two-sided Fisher’s exact test. The paired samples t-test was
applied for testing differences in continuous variables of interest between baseline and
week 12 or week 33 (Study IV). To test the difference between the ghrelin concentrations of
men and women, the independent samples t-test was used, and univariate ANOVA was
applied to test the difference in ghrelin plasma levels at baseline between normal-weight and
overweight/obese subjects with features of metabolic syndrome (Study IV). Logistic
regression (Study I) or Cox regression analyses (Study III) with appropriate covariates were
applied to evaluate whether the SNPs predicted the conversion from IGT to type 2 diabetes.
Repeated measures ANOVA was used to analyse differences between the genotype of each
SNP during the follow-up period for four consecutive measurements for the variables of
interest with appropriate covariates included in the models (Study III). Genotype*group
interaction was tested, and the study groups were analysed separately if the interaction term
was significant (Study III). Repeated measures ANOVA was also used for testing the
interaction between ghrelin concentrations and the study groups during the whole study
period with the measurements from baseline, and at week 12 and week 33 (Study IV). P-
values are for trends between all tested groups, and pairwise comparisons based on estimated
marginal means were adjusted for multiple comparisons with Bonferroni correction. The
linear mixed models analysis for repeated measures data was applied to analyse differences
between genotype combination groups in systolic and diastolic BP levels of four
measurements (Study II) as well as to test the relationship between plasma ghrelin levels and
relevant variables longitudinally (Study IV). Correlations between changes in plasma ghrelin
levels with other measurements were performed using Pearson’s correlation, and linear
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regression analysis was used to test correlations between the gene expression of ghrelin and
that of GHSR 1b in PBMCs, as well as for expression of several cytokines in PBMCs with
appropriate covariates (Study IV). Spearman correlations were used when variables were not
normally distributed after logarithmic transformation (Study IV). Relative changes in weight
and measures of glucose and insulin metabolism from baseline to year 3 were analysed with
the Kruskal-Wallis test, since data were not normally distributed even after applying several
transformations (Study III).
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5 Results
5.1 General characteristics of study populations
Both the Finnish DPS and the Genobin study included middle-aged Finnish persons with
overweight or obesity and insulin resistance. In the DPS, this high-risk group for developing
type 2 diabetes was randomly divided into an intervention and control group, with the
incidence of type 2 diabetes providing the main outcome measure [385]. During a mean
intervention period of about 3 years, a 58% relative risk reduction in the progression from
IGT to type 2 diabetes was achieved [366, 386]. Persons in the intervention group lost
significantly more weight than those in the control group during the 3-year follow-up period
(intervention group: -3.4±5.2 kg, control group: -0.6±5.2 kg, p<0.0001).
In the Genobin study, the individuals were randomised into four study groups. In this
study, only participants in the weight reduction group lost weight significantly during the
33-week intervention period (-4.6±3.9 kg, p<0.001) [369]. Subjects in both exercise groups
showed no significant change in their body weight (resistance training group: -1.0±2.6 kg,
p=0.190; aerobic training group: -1.6±3.5 kg, p=0.103), nor did the subjects in the overweight
control group (-0.2±1.5 kg, p=0.576).
Tables 13 and 14 show the baseline characteristics of the participants in the Finnish DPS
and the Genobin study, respectively.
Table 13. Baseline characteristics of the DPS participants altogether and separately in the
intervention and control group with available DNA.
Characteristic All individuals
(n=507)
Intervention group
(n=259)
Control group
(n=248)
Sex (men/women) 166/341 88/171 78/170
Age (years) 55±7 (507) 55±7 (259) 55±7 (248)
Weight (kg) 86.2±14.2 (507) 86.6±14.0 (259) 85.8±14.4 (248)
BMI (kg/m2) 31.2±4.5 (507) 31.3±4.5 (259) 31.2±4.5 (248)
Waist circumference (cm) 101.2±11.0 (505) 101.8±11.0 (258) 100.6±11.0 (247)
Systolic blood pressure (mmHg)* 138.2±17.6 (502) 139.9±17.5 (258)# 136.3±17.6 (244)#
Diastolic blood pressure (mmHg)* 85.7±9.6 (502) 85.8±9.2 (258) 85.6±9.9 (244)
Fasting plasma glucose (mmol/L) 6.14±0.75 (507) 6.11±0.77 (259) 6.16±0.74 (248)
2-h plasma glucose (mmol/L) 8.88±1.49 (507) 8.87±1.52 (259) 8.89±1.47 (248)
Fasting serum insulin (mU/L) 14.77±7.40 (461) 14.77±7.31 (234) 14.77±7.50 (227)
2-h serum insulin (mU/L) 95.17±65.10 (458) 97.94±74.26 (234) 92.27±53.91 (224)
HOMA-IR (mmol x mU x l-2) 4.11±2.29 (461) 4.09±2.25 (234) 4.11±2.33 (227)
Values are means ± SD (n); to convert values for insulin to pmol/L, multiply by 6. *Antihypertensive drugs were
being taken by 35.1% of subjects in the intervention group and 36.6% in the control group. #p=0.016 for the
comparison between intervention and control group by two-tailed t-test.
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5.2 Genetic variations in the GHRL and GHSR genes
5.2.1 Genotype frequencies of GHRL and GHSR polymorphisms
The observed genotype frequencies in all GHRL and GHSR SNPs were in Hardy-Weinberg
equilibrium. The genotype frequencies for all studied polymorphisms are shown in Table 15.
Table 15. Genotype frequencies of GHRL and GHSR SNPs in the DPS and Genobin study
populations.
GHRL SNP Genotype Genotype frequency
in DPS (n)
Genotype frequency
in Genobin study (n)
-604G/A GG
GA
AA
0.134 (68)
0.489 (248)
0.377 (191)
0.213 (16)
0.467 (35)
0.320 (24)
-501A/C AA
AC
CC
0.540 (274)
0.373 (189)
0.087 (44)
0.613 (46)
0.293 (22)
0.093 (7)
-473G/A GG
GA
AA
0.976 (495)
0.024 (12)
-
0.987 (74)
0.013 (1)
-
Arg51Gln Arg51Arg
Arg51Gln
Gln51Gln
0.943 (478)
0.055 (28)
0.002 (1)
0.933 (70)
0.067 (5)
-
Leu72Met Leu72Leu
Leu72Met
Met72Met
0.769 (390)
0.203 (103)
0.028 (14)
0.773 (58)
0.200 (15)
0.027 (2)
Gln90Leu Gln90Gln
Gln90Leu
Leu90Leu
0.730 (370)
0.250 (127)
0.020 (10)
0.773 (58)
0.200 (15)
0.027 (2)
GHSR SNP Genotype Genotype frequency
in DPS (n)
Genotype frequency
in Genobin study (n)
rs6772676 CC
CT
TT
0.229 (116)
0.485 (246)
0.286 (145)
0.280 (21)
0.413 (31)
0.307 (23)
rs474225 TT
TC
CC
0.037 (19)
0.260 (132)
0.702 (356)
0.027 (2)
0.320 (24)
0.653 (49)
rs490683 CC
CG
GG
0.091 (46)
0.424 (215)
0.485 (246)
0.133 (10)
0.333 (25)
0.533 (40)
rs9819506 GG
GA
AA
0.389 (197)
0.465 (236)
0.146 (74)
0.413 (31)
0.440 (33)
0.147 (11)
rs495225 TT
TC
CC
0.481 (244)
0.412 (209)
0.107 (54)
0.547 (41)
0.360 (27)
0.093 (7)
rs509035 CC
CT
TT
0.426 (216)
0.464 (235)
0.110 (56)
0.467 (35)
0.373 (28)
0.160 (12)
rs565105 CC
CA
AA
0.099 (50)
0.406 (206)
0.495 (251)
0.093 (7)
0.360 (27)
0.547 (75)
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5.2.2 Association between SNPs in the GHRL gene and conversion to
type 2 diabetes (Study I)
During the first three years of the DPS, 21 subjects (8.7%) in the intervention group and
51 subjects (21.4%) in the control group developed type 2 diabetes. Only the Leu72Met SNP
of GHRL was associated with conversion from IGT to type 2 diabetes. In the entire study
population, the conversion rate to type 2 diabetes was 13.2% among subjects with the
Leu72Leu genotype, 22.1% among subjects with the Leu72Met genotype and 15.4% among
subjects with the Met72Met genotype (p=0.096). In the intervention group, 6.3% of the
subjects with the Leu72Leu, 20.9% with the Leu72Met and none of subjects with the
Met72Met genotype converted to diabetes (p=0.006; Figure 7). In the control group, 20.6% of
the subjects with the Leu72Leu, 23.1% with the Leu72Met and 33.3% with the Met72Met
genotype converted to diabetes (p=0.715; Figure 7).
Figure 7. Three-year incidence of type 2 diabetes
according to the Leu72Met polymorphism in the
intervention and control group of DPS [% (number
of subjects who converted to diabetes / total number
of subjects)]. Intervention group p=0.006 and
control group p=0.715 for comparison among all
three genotypes (c2 test); white bars, Leu72Leu;
dark grey bars, Leu72Met; black bar, Met72Met
(modified from Study I [387]).
Individuals homozygous for the Leu72 allele were less likely to convert to type 2 diabetes
than were those subjects with the other genotypes in the entire DPS population (OR 0.47,
95%CI: 0.26-0.87, p=0.016) and in the intervention group separately under a dominant model
of inheritance (OR 0.28, 95%CI: 0.10-0.79, p=0.016). When a codominant model was
evaluated, persons with Leu72Met genotype had a higher risk of converting to type 2 diabetes
than did the Leu72Leu subjects in the entire DPS population (OR 2.16, 95%CI: 1.15-4.08,
p=0.017) or in the intervention group separately (OR 4.38, 95%CI: 1.50-12.75, p=0.007). In
this model, homozygosity for the Met72 allele was not associated with an increase in risk of
conversion to type 2 diabetes.
None of the GHSR polymorphisms were statistically significantly associated with the risk
of type 2 diabetes (Study III).
5.2.3 Association between SNPs in the GHSR gene and glucose
metabolism (Study III)
Differences between genotypes were observed with the rs6772676 SNP for fasting
(p/q=0.038/0.035) and 2-h plasma glucose (p/q=0.006/0.035) in the whole study population
when data were analyzed longitudinally, with heterozygotes showing the highest levels.
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In the entire DPS population, 2-h plasma glucose (Figure 8) and 2-h serum insulin levels
differed according to the GHSR rs490683 genotypes when the data were analysed
longitudinally (p/q=0.015/0.035, p/q=0.050/0.041, respectively). Subjects with rs490683-CC
genotype tended to have the lowest values.
Figure 8. 2-h plasma glucose
according to rs490683 genotypes in all
DPS participants (Study III).
Mean ± SEM are estimated marginal
means calculated from repeated
measures ANOVA with group, age and
BMI at baseline as significant
covariates. Pairwise comparisons: CC
vs. CG p=0.020, CC vs. GG p=0.295,
CG vs. GG p=0.190.
When relative changes between baseline and year 3 were analysed in the whole study
population, differences between rs490683 genotypes were seen in fasting plasma glucose,
2-h plasma glucose, 2-h serum insulin, and a trend was observed for relative change in fasting
serum insulin (Table 16). When the study groups were analysed separately, significant
differences between the rs490683 genotypes according to fasting and 2-h plasma glucose,
fasting and 2-h serum insulin were observed in the control group (Table 16), but not in the
intervention group. Specifically, in the control group these concentrations were decreased in
subjects with rs490683-CC genotype and increased in subjects with rs490683-GG genotype.
Table 16. Relative changes in fasting and 2-h plasma glucose, fasting and 2-h serum insulin
according to genotypes of the GHSR rs490683 for the entire DPS population and intervention
and control group separately.
rs490683-CC (n) rs490683-CG (n) rs490683-GG (n) P-value Q-value
Change in fasting glucose (%)
All subjects
 Intervention group
 Control group
-2.6 ± 1.7 (46)
-1.9 ± 2.0 (28)
-3.7 ± 3.2 (18)
2.1 ± 0.9 (212)
0.9 ± 1.2 (104)
3.2 ± 1.3 (108)
2.0 ± 0.8 (242)
-0.7 ± 1.1 (122)
4.7 ± 1.2 (120)
0.014
0.310
0.004
0.069
0.785
0.078
Change in 2-h glucose (%)
All subjects
 Intervention group
 Control group
-12.9 ± 3.3 (46)
-11.1 ± 4.4 (28)
-15.6 ± 5.1 (18)
4.0 ± 2.1 (211)
-0.4 ± 2.8 (104)
8.2 ± 3.0 (107)
1.5 ± 1.8 (242)
-2.0 ± 2.6 (122)
5.1 ± 2.5 (120)
0.001
0.164
0.007
0.020
0.785
0.100
Change in fasting insulin (%)
All subjects
 Intervention group
 Control group
-11.5 ± 6.0 (39)
-7.0 ± 9.7 (22)
-17.4 ± 5.7 (17)
-0.1 ± 3.0 (189)
-5.1 ± 3.6 (91)
4.4 ± 4.6 (98)
9.0 ± 5.8 (226)
-8.4 ± 3.2 (116)
27.3 ± 11.2 (110)
0.067
0.755
0.004
0.101
0.871
0.078
Change in 2-h insulin (%)
All subjects
 Intervention group
 Control group
-21.5 ± 7.6 (38)
-17.8 ± 12.1 (22)
-26.5 ± 7.3 (16)
0.1 ± 5.2 (185)
-8.0 ± 6.9 (91)
7.9 ± 7.7 (94)
1.1 ± 5.8 (219)
-11.7 ± 7.9 (112)
14.6 ± 8.5 (107)
0.045
0.339
0.029
0.086
0.785
0.245
Data are means ± SEM.
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Similar results to those with rs490683 were also observed with rs509035. In the entire
study population, 2-h plasma glucose and fasting serum insulin levels differed according to
the rs509035 genotypes when the data were analysed longitudinally (p/q=0.014/0.035 and
p/q=0.037/0.035, respectively), with rs509035-TT genotype showing the lowest values.
When relative changes between baseline and year 3 were analysed for the whole study
population, differences between rs509035 genotypes were seen in fasting plasma glucose
(p/q=0.046/0.086), 2-h plasma glucose (p/q=0.011/0.069) and 2-h serum insulin
(p/q=0.037/0.086). When the study groups were analysed separately, significant differences
between the rs509035 genotypes according to 2-h plasma glucose, fasting and 2-h serum
insulin were observed in the control group (p/q=0.038/0.267, p/q=0.050/0.300, and
p/q=0.014/0.152, respectively), but not in the intervention group. These levels were decreased
in subjects with rs509035-TT genotype in the control group during the study period.
5.2.4 Association between SNPs in the GHRL gene and blood pressure
and hypertension (Study II)
In the DPS population at baseline, the -604G/A SNP of GHRL was significantly associated
with systolic BP (p=0.019, -604GG: 132.7 ± 14.0, -604GA: 139.0 ± 19.0, -604AA:
138.9 ± 16.6 mmHg, respectively). When data were analysed longitudinally, GHRL SNPs
-604G/A, -501A/C and Leu72Met were associated with systolic and diastolic BP. Persons
with -604GG genotype had the lowest systolic and diastolic BP levels during the four
consecutive measurements (Figure 9 A, B).
Figure 9. Mean values ± SEM calculated from linear mixed model analysis. A. Systolic BP levels in
the entire DPS population. Pairwise comparisons: GG vs. GA: p=0.034, GG vs. AA p<0.001.
B. Diastolic BP levels in the entire DPS population. Pairwise comparisons: GG vs. AA p=0.001, GG
vs. GA p=0.071.
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Individuals with -501CC genotype had the highest systolic and diastolic BP levels during
the four consecutive measurements (Figure 10 A, B).
Figure 10. Mean values ± SEM calculated from linear mixed model analysis. A. Systolic BP levels in
the entire DPS population. Pairwise comparisons: AA vs. CC: p=0.013, AC vs. CC p=0.086.
B. Diastolic BP levels in the entire DPS population. Pairwise comparisons: AA vs. CC p=0.007, AC
vs. CC p=0.059.
In addition, the Leu72Met SNP was associated longitudinally with systolic (p=0.013 for
comparison among all three genotypes) and diastolic BP (p=0.017 for comparison among all
three genotypes), with Leu72Leu subjects exhibiting the lowest levels.
The four most common GHRL SNPs (-604G/A, -501A/C, Leu72Met and Gln90Leu)
represented a haplotype block and formed seven major haplotypes. The most common
haplotype with a frequency of 0.346 in the DPS population included the -604G, -501A, Leu72
and Gln90 alleles of the four SNPs. Subsequently, we compared subjects who had
simultaneously the -604GG, -501AA, Leu72Leu and Gln90Gln genotypes (0000), and
therefore harboured the most common haplotype, with all other subjects. Similar to the single
SNP analyses, subjects with the 0000 genotype combination had significantly lower systolic
(p=0.003) and diastolic BP (p=0.004) than subjects with other genotype combinations at four
consecutive measurements (Study II, Fig. 3 [377]). Although the prevalence of hypertension
was not significantly different between the subjects with the 0000 genotype combination and
the other subjects at baseline (57.7% vs. 64.7%, p=0.200), those subjects with the 0000
genotype combination had a significantly lower prevalence of hypertension at year 1 (40.0%
vs. 58.9%, p=0.006) and year 2 (41.2% vs. 58.7%, p=0.013), and a similar trend was also seen
at year 3 (46.8% vs. 59.2%, p=0.071) (Study II). When analysed with logistic regression,
these results were reinforced, and the 0000 genotype combination was found to be protective
against hypertension in year 1 (OR=0.408, 95% CI: 0.225-0.739; p=0.003), year 2
(OR=0.438, 95% CI: 0.238-0.804; p=0.008) and year 3 (OR=0.533, 95% CI: 0.285-0.999;
p=0.050) (Study II [377]).
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In the Genobin study population at baseline, the GHRL Leu72Met SNP was associated with
systolic BP (p=0.035; Leu72Leu: 138.0 ± 13.3, Leu72Met: 130.3 ± 10.3, Met72Met:
151.0 ± 2.8 mmHg). When analysed longitudinally, the association between Leu72Met SNP
and systolic BP was no longer significant (p=0.121).
5.2.5 Associations between SNPs in the GHRL or GHSR genes and
obesity (Study III)
In the DPS population at baseline, the -604G/A SNP of GHRL was significantly associated
with weight (p=0.033, -604GG: 87.6 ± 14.7, -604GA: 87.4 ± 14.8, -604AA: 84.1 ± 13.1 kg,
respectively), and the Gln90Leu SNP was associated with waist circumference (p=0.050,
Gln90Gln: 101.5 ± 10.7, Gln90Leu: 101.2 ± 11.7, Leu90Leu: 92.6 ± 9.1 cm, respectively).
When the data were analysed longitudinally, subjects homozygous for the Leu90 allele (n=10)
had significantly lower body weight over four consecutive measurements than did the subjects
with Gln90Gln (p=0.014) or Gln90Leu genotype (p=0.029; Figure 11). Subjects with the
Leu90Leu genotype also had lower BMI over the 3-year follow-up (p=0.015 for trend among
all three genotype groups) compared to subjects homozygous for Gln90 (p=0.013) or the
heterozygous subjects (p=0.029). Waist circumference was no longer significantly associated
when the data were analysed longitudinally.
In the DPS population at baseline (Study III), the GHSR SNPs were not associated with
obesity; however, in the follow-up data analysis, when the four distinct time-points were
analysed simultaneously, a difference in weight was observed between the genotypes of
rs9819506 (p/q=0.036/0.035, Figure 12).
Figure 11. Weight (kg) during the
study period of DPS according to the
three genotypes of the Gln90Leu
polymorphism. Adjusted mean values
(± SEM) were calculated from linear
mixed model analysis with sex, age,
height and fat mass (%) as covariates
included. Pairwise comparisons:
Gln90Gln vs. Leu90Leu: p=0.014,
Gln90Leu vs. Leu90Leu: p=0.029.
Figure 12. Weight according to
rs9819506 genotypes in the entire
DPS study population (Study III).
Mean ± SEM are estimated
marginal means calculated from
repeated measures ANOVA with
sex and age as significant
covariates. Pairwise comparisons:
GG vs. GA p=1.000, GG vs. AA
p=0.030, GA vs. AA p=0.116.
73
We also studied the genotype effect on changes in body size measures during the 3-year
intervention (Study III). When all subjects were analysed together, subjects with rs490683-CC
genotype lost significantly more weight than did the others (p/q=0.032/0.086, Figure 13).
When the two treatment groups were analysed separately, weight loss was most profound in
the intervention group for subjects with the rs490683-CC genotype compared to the other
genotypes (p/q=0.020/0.447), but no significant difference was observed in the weight change
between the rs490683 genotypes in the control group (p/q=0.538/0.751). No significant
differences in weight loss during the intervention period were seen with other GHSR SNPs.
5.3 In silico and in vitro analysis of the 5’-regulatory region of the
GHSR gene (Study III)
The Genomatix MatInspector software [383] was used to identify putative TF binding sites in
the 5’-region (haploblock 1) of the GHSR gene that may be implicated in the regulation of the
gene expression. Screening of 20 kb upstream of the translation initiation site resulted in the
identification of 8 SNPs which potentially disrupted one or more TF binding sites in either
one of the alleles or both. Subsequently, oligonucleotides containing one or the other allele of
each SNP were tested to identify possible differences in protein binding between the alleles of
each SNP in gelshift assays using rat hypothalami as a TF protein source. The SNPs
rs6772676 and rs490683 showed different protein binding when comparing both alleles.
Specifically, when the protein binding of the so-called “wild-type” allele was normalised to
100%, the rs6772676-T allele showed only 28% protein binding compared to the rs6772676-
C allele, whereas the rs490683-G allele showed 745% protein binding compared to the
rs490683-C allele (Figure 14). The sequence with the rs490683-G allele contains a putative
binding site for the TF NF-1, which is disrupted when G is replaced by C, changing the
sequence from GCCA to CCCA.
Figure 13. Relative weight loss according to
the different genotypes of rs490683 in all
DPS participants and separately in
intervention and control group. (Study III).
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5.4 Gene expression studies
5.4.1 Subcutaneous adipose tissue
Ghrelin mRNA expression was detected in the subcutaneous adipose tissue samples of all
study persons, with mean CT-values of 33.9 (range 32.2-36.1) at baseline. The mean ghrelin
expression at baseline was 89.3 in arbitrary units (AU) (range 20.8-276.4). The mean values
for men and women were 96.1 and 82.5 AU, respectively (p=0.228). The intervention had no
significant effect on ghrelin expression (data not shown). During the intervention, the study
groups showed no difference regarding ghrelin expression in adipose tissue (ghrelin
expression*group interaction p=0.409; group effect p=0.409). Ghrelin mRNA expression in
subcutaneous adipose tissue was not significantly associated with ghrelin plasma levels or
other metabolic parameters (data not shown).
Neither GHSR 1a nor type 1b mRNA expression could be detected in the subcutaneous
adipose tissue of our study participants (data not shown).
5.4.2 Peripheral blood mononuclear cells (Study IV)
Both ghrelin and GHSR 1b mRNA were expressed in the PBMCs of all study participants,
whereas no GHSR 1a mRNA expression could be detected. The mean ghrelin expression in
Figure 14. Differential protein binding of rat hypothalamus
nuclear protein extract (Study III). Gelshift experiments
were performed with 32P-labeled oligonucleotides
containing one or the other allele of respective single
nucleotide polymorphism (SNP). Numbers below the gels
indicate the means of three independent experiments with
standard deviation (SD) in parenthesis. Protein binding of
the “wild-type” allele was normalised to 100%.
Representative gels are shown. NS denotes non-specific
DNA-protein interactions, which are not due to specific
binding between the labelled DNA and the proteins
contained in the hypothalamus extract.
** p<0.001.
8% non-denaturing gel
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PBMCs at baseline was 107.9 in arbitrary units (AU; range 47.5-240.3), with mean CT-values
of 31.9 (range 31.1-33.3). The mean values for men and women were 99.6 and 116.9 AU at
baseline, respectively (p=0.157). The intervention had no significant effect on ghrelin
expression (data not shown). During the intervention, no differences were observed between
the study groups regarding ghrelin expression in the PBMCs (ghrelin expression*group
interaction p=0.778; group effect p=0.459); therefore, the groups were analysed together. The
mean GHSR 1b expression in PBMCs at baseline was 94.8 AU (range 5.6-619.3), with mean
CT-values of 31.0 (range 27.2-33.7) and no significant difference being seen between men and
women (mean 78.2±62.6 AU and 112.7±138.1 AU, respectively).
Ghrelin and GHSR 1b expressions were positively correlated at all three time points of
the study (Figure 15 A). In a multivariate model, ghrelin mRNA expression in PBMCs was a
significant predictor of GHSR 1b expression in PBMCs at baseline and week 33, and a trend
was also seen at week 12 (Figure 15 A).
5.4.2.1 Association with inflammatory markers (Study IV)
The expression of several cytokines related to inflammation from PBMCs was also measured
in order to determine whether a connection might exist between these cytokines and ghrelin
expression in PBMCs. Ghrelin mRNA expression in PBMCs was found to have a significant
positive correlation with TNF-? expression at baseline and week 12, with the same trend
being seen in week 33 with borderline significance (Figure 14 B).
Figure 15. Variation of GHSR 1b (A) and TNF-? (B) mRNA expression in PBMCs according to
tertiles of ghrelin mRNA expression in PBMCs at baseline, week 12 and week 33 of the Genobin
study separately, respectively. Data are means and SEM. P-values obtained from linear regression
analysis with GHSR 1b or TNF-? as dependent variable, respectively, and sex, age, BMI at the given
time point as covariates; ? = standardised regression coefficient.
IL-1? expression in PBMCs showed no correlation with ghrelin expression in the PBMCs at
baseline (standardised regression coefficient ?=0.078, p=0.581). Nevertheless, at week 12
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??=0.278, p=0.040) and week 33 (?=0.312, p=0.022) ghrelin expression was a significant
predictor of IL-1? expression in PBMCs. In addition, the relative change in ghrelin expression
in PBMCs from baseline to week 33 and relative change in IL-1? expression in PBMCs
correlated strongly with each other (r=0.503, p<0.001).
5.4.2.2 Association between SNPs in the GHRL gene and ghrelin expression
in PBMCs (Study IV)
In the Genobin study population at baseline, the GHRL -604G/A SNP was associated with
ghrelin mRNA expression in PBMCs, with -604AA individuals having the lowest levels
(p=0.001; -604GG: 137.2 ± 55.6, -604GA: 113.9 ± 40.3, -604AA: 83.3 ± 20.5 AU). Similarly,
the -501A/C SNP was associated with ghrelin mRNA expression in PBMCs, with -501CC
persons having the lowest levels (p=0.025; -501AA: 116.4 ± 43.1, -501AC: 101.1 ± 44.6,
-501CC: 75.6 ± 20.5 AU).
Significant differences in the three measurements conducted during the study period were
observed between the ghrelin mRNA expression in PBMCs and both the -604G/A and
-501C/A polymorphisms. Study participants with the -604AA genotype of the -604G/A SNP
had lower ghrelin expression in PBMCs than those with -604GG (p=0.003) and -604GA
genotypes (p=0.060) (Figure 16 A). Similarly, individuals with the -501CC genotype of the
-501A/C polymorphism had lower ghrelin expression in PBMCs than those with the -501AA
genotype (p=0.009) (Figure 16 B). BMI at baseline, sex, age or study group did not
significantly contribute to the different expression levels between the genotypes of either of
the polymorphisms.
Figure 16. Ghrelin mRNA expression in PBMCs at three time points of the Genobin study according
to the -604G/A (A) and the -501A/C (B) polymorphism of the GHRL gene (Study IV [370]). Values
are estimated marginal means calculated from repeated measures ANOVA. A. Pairwise comparisons:
GG vs. GA p=0.397, GG vs. AA p=0.003, GA vs. AA p=0.060. B. Pairwise comparisons: AA vs. AC
p=0.188, AA vs. CC p=0.009, AC vs. CC p=0.332.
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5.5 Plasma ghrelin concentrations (Study IV)
5.5.1 Plasma ghrelin concentrations at baseline
At baseline, the mean fasting plasma ghrelin concentration in the whole Genobin study
population (n=75) was 825 pg/ml (range 451-1468 pg/ml). The mean values for men and
women were 795 and 854 pg/ml, respectively, and did not significantly differ from each other
(p=0.283). Multiple linear regression analysis demonstrated that fasting serum insulin
concentrations (?=-0.483, p<0.001), insulin concentrations during an OGTT (30 min serum
insulin: ?=-0.368, p=0.003; 120 min serum insulin: ?=-0.457, p<0.001), insulin sensitivity
index (SI) (?=0.343, p=0.006) and HDL cholesterol (?=-0.300, p=0.016) were significant
independent predictors of ghrelin concentration at baseline. A trend towards a negative
association between ghrelin plasma levels and acute insulin response (AIR) was seen
??=-0.236, p=0.068). Weight, BMI or waist circumference was not correlated with plasma
ghrelin levels in Genobin study participants at baseline.
Plasma ghrelin levels in the overweight/obese study participants were significantly lower
than those in normal-weight persons (p=0.005, adjusted for age and sex; mean fasting plasma
ghrelin concentration of normal-weight persons 1056 pg/ml, range 622-1510 pg/ml).
5.5.2 Plasma ghrelin concentrations during interventions
The association between fasting plasma ghrelin levels and fasting serum insulin
concentrations over the time period of the Genobin study was examined using the linear
mixed models analysis. The results show that fasting serum insulin was a significant predictor
of fasting plasma ghrelin levels (p=0.024). When weight, BMI or waist circumference was
included separately as a covariate into the model, it was found that these measures of fat
mass/obesity significantly contributed to the plasma ghrelin concentration (p=0.050, p=0.025,
p=0.023, respectively), with fasting insulin concentration no longer being significant (p=0.075
- p=0.128). SI did not significantly contribute to the ghrelin concentrations when tested with
this multilinear model. However, AIR significantly influenced the fasting plasma ghrelin
concentrations over the study period (p=0.001), even after adjusting for the effect of weight,
BMI, waist circumference and SI. In fact, weight, BMI and waist circumference were strongly
associated with plasma ghrelin longitudinally (p=0.013 for weight, p=0.004 for BMI, p=0.005
for waist circumference).
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When participants from the weight reduction group (n=28) were compared to those from
the control group (n=18), the interaction term for plasma ghrelin*group indicated a trend for
difference (p=0.067): the plasma ghrelin concentrations differed significantly between the
groups at week 12 (p=0.042) and at week 33 (p=0.024), with higher levels being observed in
the weight reduction group (Figure 17).
Figure 17. Plasma ghrelin concentrations in the
weight reduction and control groups of the
Genobin study. Repeated measures ANOVA
with baseline plasma ghrelin levels as
covariate. Values are estimated marginal means
± SEM. Interaction term plasma ghrelin*group
p=0.067 (Study IV [370]).
Correlation analysis on all study participants showed an inverse relationship between the
relative weight change and relative change in plasma ghrelin from baseline to week 33
??=-0.294, p=0.010).
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6 Discussion
6.1 Methodological considerations
6.1.1 Study populations
Participants of DPS and the Genobin study were carefully selected and clinically well
characterised. All persons in both studies were Finnish. The current Finnish population is
believed to originate from a small group of individuals who settled in the southwest part of
the country about 2000 years ago. Since the initial immigration, the population has continued
to be relatively isolated, with little external migration into the area [388]. Therefore, the
Finnish population has been designated as a model population for human genetic studies and
even smaller sample sizes can lead to reliable results.
The individuals investigated in Studies I, II and III were participants of the Finnish DPS
[366]. They are a representative sample of middle-aged, overweight Finnish persons with IGT
who were at high risk of developing type 2 diabetes. Nowadays, the DPS population might be
considered small for genetic association studies. However, due to the fact that DPS is a
longitudinal study and has consisted of a relatively homogenous population of Finnish
individuals with IGT, the number of participants (n=507) seems appropriate.
The participants in the Genobin study who were investigated in Study IV had either IGT
or IFG and two additional features of the metabolic syndrome and were thus also at high risk
of developing type 2 diabetes. Because the Genobin study was designed as a controlled
lifestyle intervention, the number of individuals in this study (n=75) is low for a genetic
association study; nevertheless, some statistically significant associations were found.
However, the small sample size diminishes the power to detect further associations.
6.1.2 Measurements of obesity
Overweight or obesity was determined by measuring body weight and height, and calculating
BMI. BMI is an adequate and simple measure of obesity for large-scale studies, since it has
been shown to correlate with body fat, morbidity and mortality [389]. Waist circumference is
an important measure of obesity risk and a practical surrogate marker of visceral abdominal
fat [389].
6.1.3 Measurements of insulin resistance
Fasting insulin concentrations and HOMA-IR were used as surrogate measures of insulin
resistance in Studies I, II and III. Both fasting insulin and HOMA-IR have proved to be a
reasonably good marker of insulin resistance [390]. The golden standard for insulin sensitivity
is the euglycaemic hyperinsulinaemic clamp technique [391]. However, in large studies, such
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as DPS, this method is not feasible. In the smaller Genobin study, SI and AIR were calculated
from FSIGT (Study IV). Those indices inferred from FSIGT have been shown to correlate
well with those derived from clamp studies and thus provide valid measures of insulin
sensitivity [392-394].
6.1.4 Determination of SNPs
Polymorphisms in the GHRL gene in DPS and Genobin study populations were genotyped
with the PCR-RFLP method (Studies I, II and IV). RFLP analysis is a sensitive and reliable
method for the detection of SNPs in candidate genes. The specificity of restriction enzymes is
very high. Recently, newer and less time-consuming methods have been introduced;
therefore, the SNPs in the GHSR gene were genotyped with TaqMan Allelic Discrimination
assays (Study III). This method is robust and accurate and allows fast, direct detection with
high sample-to-sample reproducibility. In both methods, a representative sample was repeated
to confirm the genotype in addition to reanalysis of samples for which the result was unclear.
6.1.5 Gene expression
The primers and probes in the gene expression assay for GHSR 1b (Applied Biosystems assay
ID Hs01031463_s1) were designed within one exon, because GHSR 1b is encoded by a single
exon. Such an assay detects genomic DNA and should use as a control RNA which has not
been reverse transcribed. Unfortunately, by this time, I had already reverse transcribed all of
the limited amount of RNA samples available. Therefore, it was no longer possible to provide
a control RNA sample to rule out DNA contamination. This may have obscured the results.
Ghrelin mRNA expression was detected in subcutaneous adipose tissue with mean
CT-values of 33.9, and a range of 32.2 to 36.1. IL-6 mRNA expression was detected in
PBMCs with mean CT-values of 34.9, and a range of 31.8 to 37.0. CT values greater than 35
approach the sensitivity limits of the real-time PCR detection system, and thus those results
have to be interpreted with caution.
6.1.6 Promoter analysis
In silico screening
As the initial step in gene expression, transcription is central to regulatory mechanisms.
Components of transcriptional regulation include TFs that bind to specific TF-binding sites
(either proximal or distal to a transcription start site), interactions between bound TFs and
cofactors, as well as the influence of chromatin-structure [395]. Several computational
methods are available for identifying the regulatory sequences that control the rate of
transcription initiation of specific genes of interest [395].
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In the present study, Genomatix MatInspector software was used to determine putative TF
binding sites which are disrupted by SNPs in the GHSR promoter (Study III). MatInspector is
a software tool that utilises a large library of position weight matrix descriptions for TF
binding sites to locate matches in DNA sequences [383]. The matrices in the MatInspector
library are derived from single publications with either a nucleotide distribution matrix or a
list of binding sites, or from several papers that have published individual binding sites. It
must be noted that not all the sites found are necessarily functional in the particular biological
context [383].
Gelshift assays
For gelshift assays, rat hypothalami nuclear extract was used as a source of TF protein. Since
no further supershift assays with specific antibodies against NF-1 were conducted, it can only
be presumed that the results are specific and thus the oligo-sequence may as well be bound by
a different unknown protein. Furthermore, protein binding to a TF-binding site in vitro does
not always imply functionality in vivo.
6.1.7 Measurement of plasma ghrelin concentration
The plasma ghrelin levels reported in Study IV are fasting plasma total ghrelin concentrations.
Overnight fasting plasma levels of ghrelin have been shown to correlate well with the 24-h
integrated area under the curve values of ghrelin [79, 94]. However, by measuring only total
ghrelin, individual effects of acylated and des-acyl ghrelin or a change in acyl/des-acyl
ghrelin ratio may be overlooked, since acylated and des-acyl ghrelin forms may induce
different physiological and metabolic effects [146, 218].
For participants in DPS, plasma ghrelin concentrations are not available.
6.1.8 Statistical analyses
Investigating many genetic markers and their interactions for an association with multiple
phenotypes and quantitative traits raises the possibility of finding false positive results; that is,
it increases the risk of type I errors. Bonferroni corrections for multiple testing are currently
considered a rather conservative approach and may “overcorrect” the threshold level, thereby
increasing the chance of making type II errors, i.e., introducing false negative results. Thus, to
correct for multiple testing, we calculated the FDR, expressed as a q-value, for given
p-values. Associations with a significant p-value, but a high q-value must be cautiously
interpreted and are more likely to be false-positive findings.
Some associations may be overlooked because of a lack of adequate statistical power due
to the low allele or genotype frequencies of some variants investigated in the studies
presented in this thesis or due to the limited sample sizes of the studied populations. In
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general, findings must be cautiously interpreted and can be regarded tentative until they are
corroborated, i.e., replicated in other studies and populations.
6.2 General discussion
6.2.1 Ghrelin and ghrelin receptor and type 2 diabetes and glucose
metabolism (Study I, Study III)
In the series of studies conducted, one SNP in the GHRL gene, but none of the SNPs in the
GHSR gene, was associated with the conversion from IGT to type 2 diabetes in the DPS.
Three SNPs in the GHSR gene were associated with measures of glucose and insulin
metabolism.
In Study I, the Leu72Met variant of the GHRL gene was associated with type 2 diabetes.
Individuals with the Leu72Leu genotype developed less frequently type 2 diabetes than did
those with the Met72 allele or the Leu72Met genotype. This was true for the whole DPS
population as well as for the intervention group separately, suggesting that subjects with the
Leu72Leu genotype benefited most from lifestyle intervention to reduce the risk of
conversion from IGT to type 2 diabetes. Individuals with the Met72 allele in the intervention
group, on the other hand, developed almost as often diabetes as did control subjects. Whether
more drastic lifestyle changes may be needed in persons with the Met72 allele to prevent the
conversion to type 2 diabetes remains unknown. Moreover, in the intervention group, no
converters to type 2 diabetes with Met72Met genotype were found, while individuals in the
control group who were homozygous for the Met72 allele showed the highest percentage of
converters. Nevertheless, the Met72Met genotype was not significantly associated with the
incidence of type 2 diabetes, perhaps due to the small number of subjects with this genotype.
In a recent study, metabolic syndrome was more prevalent among persons with the Met72
allele, while the Leu72Met SNP was not associated with type 2 diabetes, HOMA-IR or insulin
secretion [346]. A reduced first-phase insulin secretion in OGTT in obese children carrying
the Met72 allele has been reported [338], which might suggest a defect in the insulin secretion
of those subjects. However, in a more recent study, the Leu72 allele was associated with
higher fasting insulin and HOMA-IR values, and individuals with the Met72Met genotype
displayed the highest insulin sensitivity [359]. Furthermore, in many of the previously
conducted studies, Leu72Met was not associated with type 2 diabetes or related phenotypes
[14, 340, 341, 346, 358]; thus, it is difficult to speculate about a possible mechanism behind
the associations seen in the present study. Moreover, the functional significance of the
Leu72Met SNP remains uncertain. It lies outside the region where the mature ghrelin product
is encoded, but it may play a significant role in posttranslational processing.
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Regarding polymorphisms in the GHSR gene, Vartiainen et al. [362] showed that subjects
with rs495225-CC genotype had highest area under the insulin curve values and IGFBP-1
concentrations. In the DPS population, rs490683 and rs509035 were associated with several
measures of glucose and insulin metabolism over four consecutive measurements, as well as
when analysed as relative changes of these measures. Beneficial changes in insulin and
glucose metabolism could only be observed in the control group, and specifically in
individuals with rs490683-CC and rs509035-TT genotypes. The control group in the DPS
trial can be considered as a prospective cohort of people at high risk of diabetes. Since
changes in the measures of glucose and insulin metabolism during the study period were only
observed in the control group, this indicates that the rs490683-CC genotype and the
rs509035-TT genotype are beneficial or protective genotypes.
6.2.2 Ghrelin and hypertension (Study II)
DPS participants who had simultaneously the -604GG, -501AA, Leu72Leu and Gln90Gln
genotypes had the lowest systolic and diastolic BP levels at baseline and consistently
throughout the 3-year follow-up compared to all other genotypes. These persons also had a
lower prevalence of hypertension and a lower risk of hypertension compared to all other
subjects.
Recently, ghrelin has been shown to participate in central cardiovascular and sympathetic
regulation [201, 203, 208, 213, 396]. Ghrelin may have important direct cardiovascular effects
through GH-independent mechanisms [213, 397, 398]. It has been shown to decrease BP
[201, 208, 211], probably by acting at the nucleus of the solitary tract, one of the most
important brain regions regulating BP and the sympathetic nervous system [209, 212, 213].
Although the Leu72Met SNP has not previously been associated with hypertension [354]
or BP [76], Ukkola et al. [335] reported that female Met72 carriers had the lowest prevalence
of hypertension compared to Leu72Leu subjects, in contrast to the findings in Study II.
Previous studies have not found an association between the promoter polymorphisms
-604G/A and -501A/C and ghrelin plasma levels [343, 359]. The Gln51 allele of the
Arg51Gln SNP has been reported to be a risk allele for hypertension [355]. In our study this
SNP was not associated with either BP or hypertension.
Low plasma ghrelin levels are inversely correlated with systolic and diastolic BP in
different study populations [76, 309, 310] and associated with hypertension [76], but data on
associations between ghrelin polymorphisms and ghrelin plasma levels are sparse. As plasma
ghrelin measurements were not available in this study, it is difficult to interpret the observed
relationship and its biological significance. No data are available to date concerning the
functional relevance of any of the described polymorphisms. Furthermore, none of the
described promoter variants is located at binding sites of known TFs. Therefore, the
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mechanisms mediating an association between GHRL polymorphisms and BP regulation
remain yet to be elucidated, and other studies are needed to confirm the present findings.
In general, the conflicting findings between genetic association studies could be due to several
factors, including the heterogeneity of the study population or the phenotype. Different results
could also be attributed to true differences in allelic association with disease phenotype in
different populations.
6.2.3 Ghrelin and ghrelin receptor and obesity (Study III)
In this series of studies, one rare SNP in the GHRL gene was associated with weight and two
SNPs in the GHSR gene were associated with weight and weight loss during the intervention
in the Finnish DPS.
Ghrelin has been implicated in the development of obesity. Numerous studies on several
polymorphisms in the GHRL gene have been undertaken and have provided a large amount of
results. The Gln90Leu SNP of the GHRL gene was associated with weight in the DPS
population. The Leu90Leu genotype with a low frequency, between 2 and 2.7% in the tested
study populations, showed the lowest values for weight. Previously, this SNP has not been
associated with obesity [264, 347, 359]. Only one study has reported a higher frequency of
Leu90 allele among extremely obese children but considered this finding to be a false positive
association, since a second control group of underweight students had the same Leu90 allele
frequency [353]. The Leu90Gln SNP lies in the region coding for obestatin, a recently
discovered peptide derived from the same GHRL gene and prepro-peptide but possibly having
an opposite, anorexic action [24-26], although this is widely debated [29, 30, 399].
Nevertheless, this could provide an explanation for the negative results reported previously.
The Leu72Met variant is the most studied polymorphism in the GHRL gene. The Met72
allele has been variably associated with earlier age at onset of obesity and higher BMI [264,
337-340], or with lower BMI [335, 341]. Some studies have been unable to find an
association with the Leu72Met SNP and obesity [344, 345, 347, 348], or with weight loss
[349]. A recent prospective study showed that persons with the Gln51 and/or Met72 allele lost
body weight faster than did those patients with a genotype combination of Arg51Arg and
Leu72Leu [360]. However, these results need to be interpreted with caution, since these
analyses were not adjusted for baseline weight. In the DPS population, no association could
be found between Leu72Met and obesity (Study I).
In Study III, two SNPs (rs490683 and rs9819506) in the promoter region of the human GHSR
gene were associated with body weight and BMI. The GHSR SNP rs9819506, which has not
been examined in previous studies, showed an association, and individuals with
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rs9819506-AA genotype showed the lowest values for body weight and a trend for BMI
during the 3-year follow-up of the DPS. Interestingly, subjects with the rs490683-CC
genotype displayed the highest weight loss in the whole study group, as well as in the
intervention group, when assessed separately. Previously, Baessler et al. [351] showed an
association between GHSR haplotypes and obesity. The so-called “susceptible” haplotype
tested in that study was found more often in obese individuals and also included the
rs490683-C and rs509035-T alleles. These results might be considered contradictory to those
found in DPS, where the rs490683-CC genotype appears to be a “beneficial” genotype.
However, these different results could also be attributed to differences in study designs and
study populations, thus making it difficult to compare data from a longitudinal study with
individuals at high risk of type 2 diabetes and a cross-sectional study carried out in a different
population. A more recent study, however, could not point out a clear relationship between
GHSR SNPs and obesity [350]. Wang et al. [352] showed that obese children and adolescents
had a higher rs495225-T allele frequency than underweight subjects, but this trend could not
be confirmed in their further studies, leading them to conclude that there is no evidence for
the involvement of GHSR SNPs in body weight regulation.
To test the potential functional relevance of SNPs in the 5’-region of the GHSR gene, an
in silico promoter analysis was carried out to identify SNPs disrupting putative TF binding
sites. Gelshift assays using nuclear protein extracts from rat hypothalamus were used to test
oligonucleotides with each allele of each SNP. Nuclear proteins bound to the sequence
containing rs490683G with much higher affinity than to rs490683C. At this position, a
putative NF-1 binding site exists and is disrupted by rs490683, changing the sequence from
GCCA to CCCA. The NF-1 family of site-specific DNA-binding proteins functions both as
cellular TFs in the regulation of gene expression and as replication factors for adenovirus
DNA replication [400]. The binding specificity of NF-1 is equivalent to both the TGGCA-
binding protein [401] and the CAAT-box TF [402, 403]. The NF-1 protein binds as a dimer to
the dyad symmetric consensus sequence TTGGC(N5)GCCAA on duplex DNA, although
NF-1 can also bind specifically to individual half sites (TTGGC or GCCAA) with somewhat
reduced affinity [400]. NF-1 has been shown to activate transcription [400], and it can be
speculated that in individuals with rs490683-GG genotype, where the NF-1 half site is intact,
GHSR expression is enhanced, thus potentially leading to an increase in receptor signalling
and ultimately to an increase in appetite [404]. It has recently been shown that GHSR signals
with ~50% activity even in the absence of agonist [152]. This implies that control of the
expression level of the receptor is directly correlated to its signalling activity [323]. It was
shown that during prolonged fasting, GHSR expression in the hypothalamus is increased,
which could contribute to the amplification of ghrelin action [404] and could be expected to
result in a ghrelin-independent increase in receptor signalling and thereby an increase in
appetite [323]. The GHSR polymorphism rs490683 might lead to increased ghrelin receptor
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expression, and in the present study, persons with rs490683-GG genotype lost less weight
during a lifestyle intervention than did those individuals with the rs490683-CC genotype.
One of the investigated GHSR SNPs is located in the exon, but the substitution does not
lead to an amino acid change. Therefore, it is not anticipated that the binding of ghrelin to its
receptor is altered. However, naturally occurring mutations leading to amino acid changes in
the ghrelin receptor have been previously characterised in patients with short stature and
obesity developing during puberty [352, 405]. Those mutations have been shown to lead to a
loss in constitutive activity of GHSR [405, 406]. Furthermore, in vitro experiments and
proteometrics analysis of the constitutive and ghrelin-induced activities of wild-type and
mutant ghrelin receptors have been carried out previously [407, 408]. In vitro, GHSR
missense-mutations were shown to affect basal activity (ligand-independent signalling) and
GHSR expression, as well as to alter the response to ghrelin (agonist activity) and inverse
agonist function [409]. In addition, animals in which GHSR activity has been knocked out
display lower body weight, reduced food intake, and increased fat burning on a high-fat diet
[148, 322, 332-334]. Taken together, genetic factors, e.g., the rs490683 SNP in the GHSR
gene, which lead to increased ghrelin receptor expression, may contribute to increased GHSR
signalling and ultimately higher body weight.
6.2.4 Determinants of plasma ghrelin concentrations (Study IV)
In Study IV, plasma ghrelin levels correlated negatively with fasting serum insulin and insulin
levels during the OGTT but positively with SI and serum HDL cholesterol concentration
cross-sectionally, a finding supported by previous literature [75, 76, 79, 307, 310]. However,
in the longitudinal data, measures of central obesity seem to be more important contributing
factors explaining low ghrelin concentrations in persons with the metabolic syndrome than
insulin or insulin sensitivity. Interestingly, low AIR was also associated with high ghrelin
concentrations longitudinally, suggesting that first-phase insulin secretion per se could
influence ghrelin secretion. However, it was previously suggested that early insulin response
has no effect on plasma ghrelin [114].
Numerous studies have been carried out to unravel the ambiguous relationship between
insulin and ghrelin. In humans, insulin inhibits ghrelin secretion [73, 74]. An increase in
insulin after glucose administration could contribute to the inhibitory effect of glucose on
ghrelin secretion [69-72]. However, simultaneous administration of insulin and glucose does
not change ghrelin levels [72] nor during euglycaemic clamp, insulin suppresses ghrelin [107,
108]. Administering ghrelin to humans has been shown to inhibit insulin secretion, though no
effect was observed on insulin response during OGTT [215-217]. Co-administration of
acylated and des-acyl ghrelin prevented the acute hyperglycaemic and hyperinsulinaemic
effects of acylated and des-acyl ghrelin when administered alone [218].
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The degree of insulin resistance or diabetes status could have an influence on the
relationship between ghrelin and insulin. During hyperinsulinaemic-euglycaemic clamp tests,
insulin decreased plasma ghrelin dose-dependently in healthy humans, but not in type 2
diabetic patients, perhaps due to the presence of insulin resistance [410]. Another clamp-study
showed that hyperinsulinaemia (with concomitant hyperglycaemia) at concentrations typically
seen in insulin-resistant persons did not affect plasma ghrelin but was decreased only at
pharmacological insulin concentrations [104].
However, it is not clear whether insulin resistance plays a causal role in lower ghrelin
concentrations, or whether ghrelin concentrations may be downregulated in insulin resistance
as a physiological response to a hyperinsulinaemic state. Independently from the mechanisms
mediating the endocrine or paracrine/autocrine impact of ghrelin on insulin secretion, it is
clear that ghrelin influences insulin secretion and glucose metabolism; insulin and glucose
levels, in turn, negatively influence ghrelin secretion, thus indicating the existence of a
feedback mechanism linking ghrelin with the endocrine pancreas and glucose metabolism.
The possible mechanisms behind the relationships between insulin, insulin resistance, insulin
secretion and ghrelin concentrations cannot be explained based on the present study due to its
descriptive nature.
Overweight or obese participants with metabolic syndrome in the Genobin study display
lower ghrelin levels than do normal-weight persons, which is in line with the literature.
However, in the present study, normal-weight persons were significantly younger than
overweight/obese individuals, and it has been suggested by some authors that ghrelin levels
decrease with increasing age [128, 129]. Although age and ghrelin levels did not correlate in
the Genobin study, age may be another factor explaining lower ghrelin levels in persons with
obesity and insulin resistance.
SNPs in the GHRL gene may also contribute to the variation in plasma ghrelin
concentrations. The Leu72Met SNP is associated in some studies with Met72 allele carriers
showing the highest total [359] or acylated ghrelin concentrations [342] and others showing a
trend for high total ghrelin levels with Met72 allele carrier status [76, 335] or no association
[264, 361]. The Gln51 allele of the Arg51Gln SNP was associated with low ghrelin levels [76,
335], but not in all studies [264, 361]. In Study IV, genetic variations in the GHRL gene were
not associated with plasma ghrelin concentrations. However, due to the limited sample size
and thus low numbers of individuals in each genotype group, it cannot be excluded that this
study was underpowered to detect a difference according to different SNP genotypes. On the
other hand, it must be noted that ghrelin is mostly produced by X/A-like cells of the oxyntic
gland, an endocrine cell type in the submucosal layer of the stomach. The X/A-like cells
contain round, compact, electrondense granules that are filled with ghrelin [2] and ghrelin is
secreted into the blood stream and thereafter circulates throughout the whole body [411, 412].
Thus, other factors affecting the release of ghrelin from the stomach may be more important
factors for ghrelin concentrations than genetic variation in the GHRL gene.
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6.2.5 Effect of lifestyle intervention on plasma ghrelin concentrations
(Study IV)
The majority of studies undertaken have shown an increase in total ghrelin levels upon diet-
induced weight loss in obesity [267-273]. In the present study, however, diet-induced weight
loss did not result in an increase in plasma ghrelin levels; instead, ghrelin concentrations in
overweight/obese control subjects significantly decreased over the study period. Since
participants in the Genobin study were all insulin resistant, it could be speculated that
overweight/obese subjects with IGT or IFG experience a gradual decrease in plasma ghrelin
levels, when they are not undergoing lifestyle changes. It may be that the absence of weight
loss in obesity may further decrease plasma ghrelin levels over time. Supporting this
hypothesis, the increased plasma ghrelin levels achieved by weight loss through dietary
restrictions returned to baseline after a weight maintenance period of six months in a recent
study [277].
In the previous literature, only one weight loss study reported an increase in plasma total
ghrelin concomitant with a decrease in weight specifically in subjects with metabolic
syndrome [272]. Their dietary approach was not comparable to the one used in the Genobin
study, as the subjects were 12 weeks on a commercial South Beach diet, a carbohydrate-
restricted diet with fat intake up to 62E%, whereas participants in the present study received
individualised counselling on a recommended diet based on dietary records. Another recent
study [273] with hyperlipidaemic overweight and obese females has reported an increase in
fasting total ghrelin. The mean weight loss of 14.5±3.1% was higher than in the present study
(4.8±3.8%), which may explain the difference concerning the increase in ghrelin
concentrations.
The new finding in the present study is the decrease in plasma ghrelin in the control group
with an absence of lifestyle intervention. Previous studies reporting no change in total plasma
ghrelin during weight loss have been either conducted with children [275, 276]; in healthy
young adults with moderate overweight [274, 294]; or in one study [277], the increase in total
plasma ghrelin after active weight loss was not sustained during weight maintenance.
The Genobin study was not designed to test the effect of a specific macronutrient
composition or a change in macronutrient composition on plasma ghrelin levels; therefore, no
strict dietary regime was imposed on the persons in the weight reduction group. Rather, the
objective was to give the participants advice to change their habits long-term, thus mimicking
the real-life situation in clinical practice. In the present study, fat intake decreased and protein
intake increased significantly from baseline to the end of the study in the weight reduction
group, whereas the carbohydrate intake remained stable; however, no association was
observed between the relative change in plasma ghrelin and changes in fat intake and protein
intake from baseline to the end of the study. Therefore, conclusions about the contribution of
specific macronutrients on ghrelin concentrations cannot be made based on the present study.
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In many weight loss studies, an exercise component is also included in the lifestyle
program, thus making it impossible to dissect the exclusive effect of prolonged exercise on
ghrelin levels. With the design of the Genobin study, the effects of dietary intervention and
exercise intervention can be distinguished. In this study, no changes in plasma ghrelin levels
were observed in the resistance or aerobic exercise groups. This may be partly explained by
the absence of weight loss or low intensity of exercise. On the other hand, it may suggest that
exercise has little effect on ghrelin concentrations. In fact, there is evidence that at least acute
exercise does not alter ghrelin levels [83-92]. Studies investigating the effect of weight loss
through exercise without diet changes have shown either an increase [280, 281] or no change
[282] in ghrelin concentrations.
6.2.6 Gene expression of ghrelin and ghrelin receptor in PBMCs and
adipose tissue (Study IV)
Ghrelin and ghrelin receptor expression in PBMCs have not been studied in patients with
metabolic syndrome undergoing lifestyle modification. Human ghrelin mRNA expression has
been shown in T-lymphocytes, B-lymphocytes, and neutrophils from venous blood of healthy
volunteers [48, 50, 51]. Study IV shows that ghrelin mRNA is also expressed in the PBMCs of
subjects with metabolic syndrome, though with great individual variations in expression
levels. The main aim of this study was to study PBMCs and their applicability as a surrogate
marker for ghrelin metabolism before versus after moderate weight loss. PBMCs from venous
blood samples are the most accessible tissue for analysis of gene expression and the least
demanding for the patients compared to biopsies of other tissues. Metabolic derangements
associated with metabolic syndrome potentially affect all cells in the body, and the resulting
changes in gene expression may also be sampled in PBMCs. However, ghrelin expression in
PBMCs was not influenced by the different interventions prescribed to the study participants,
nor was there any evident difference between overweight/obese compared to normal-weight
persons. Furthermore, ghrelin expression was not influenced by measures of adiposity, nor
did it correlate with plasma ghrelin levels. Interestingly, polymorphisms of the ghrelin
promoter region, the -604G/A and -501A/C variants, markedly modified ghrelin gene
expression in PBMCs, which may partly explain the individual variation of ghrelin expression
in PBMCs. Differences in ghrelin gene expression in PBMCs according to SNPs in the GHRL
gene are one factor contributing to the variation, in addition to the normal extent of inter-
individual variation which has been shown in healthy humans [413].
In the present study, GHSR 1b mRNA was also expressed in PBMCs, whereas GHSR 1a
mRNA could not be detected. Ghrelin was positively correlated to TNF-? and IL-1?
expression in PBMCs over the whole study period, and a positive correlation was seen
between changes in the expression of ghrelin and IL-1? from baseline to the end of the study.
A previous study has shown that ghrelin treatment inhibited production of pro-inflammatory
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cytokines by PBMCs via a GHSR-specific pathway [51]. It was further reported that ghrelin
inhibited IL-6 and TNF-? mRNA expression in primary human T cells, which supports a role
for ghrelin in the transcriptional regulation of inflammatory cytokine expression [51]. Anti-
inflammatory effects have also been reported for ghrelin mediated through activation of
GHSR 1a in human endothelial cells [414].
On the contrary, in the Genobin study, ghrelin expression directly correlated with TNF-?,
IL-1? and IL-6 expression in PBMCs. However, only GHSR type 1b was expressed in PBMC
samples, whereas the expression of GHSR 1a was too low to be detected. Recently, GHSR 1b
has been described as a dominant-negative mutant of GHSR 1a, resulting in attenuation of its
constitutive signalling [155]. The inhibition of pro-inflammatory cytokines in PBMCs has
been shown to be GHSR 1a-specific [51, 414]. It can be hypothesized that in the present
study, higher expression of ghrelin led to a higher expression of pro-inflammatory cytokines
due to the higher expression of GHSR 1b compared to GHSR 1a, and the concomitant
attenuation of GHSR 1a action.
Ghrelin mRNA was expressed in the subcutaneous adipose tissue of participants in the
Genobin study. Only two earlier studies reported gene expression in adipose tissue [48, 52].
Knerr et al. [52] reported ghrelin expression in subcutaneous and visceral adipose tissue with
huge intraindividual variations. They could not find a significant correlation between ghrelin
expression in different adipose tissues and serum concentration, nor did they find correlations
with other metabolic parameters. In accordance with those findings, our results show that
ghrelin mRNA expression in subcutaneous adipose tissue was not significantly associated
with ghrelin plasma levels or other metabolic parameters in our study subjects.
In the present study, neither GHSR 1a nor GHSR 1b could be detected in subcutaneous
adipose tissue. In previous reports, GHSR 1a was shown to be expressed in human omental
fat [156] and GHSR 1b in adipose tissue [48]. Although the presence of ghrelin and its
receptors has been shown, it is unlikely that ghrelin has an autocrine effect in adipose tissue,
due to the low expression levels reported.
91
7 Conclusions and future implications
These studies were conducted to investigate associations between variations in the GHRL and
GHSR genes and various phenotypes related to obesity and type 2 diabetes. Furthermore, the
studies investigated the role of ghrelin plasma concentrations and gene expression in PBMCs
and adipose tissue within the context of the metabolic syndrome and lifestyle interventions.
From the studies conducted, the following conclusions can be drawn:
Study I:
The Leu72Met SNP of the GHRL gene was associated with type 2 diabetes in the DPS
population, but in light of the previous literature and the relative weakness of the association,
this SNP cannot be regarded as a risk factor for developing type 2 diabetes.
Study II:
A common genotype combination of GHRL SNPs was associated with low blood pressure
levels and lower risk of hypertension. The associations of SNPs in the GHRL gene found in
the present study are not supported by previous association studies and have not been
replicated by other research groups thereafter. Thus, it can be concluded that GHRL SNPs do
not markedly modify the risk of investigated metabolic diseases and may not be used as
markers for risk assessment in a clinical setting.
Study III:
One SNP in the promoter of the GHSR gene was associated with weight loss, and in vitro
experiments suggested that this SNP, which disrupts a putative TF binding site, may affect
protein binding to this regulatory site, and thus may affect GHSR expression and ultimately
appetite and food intake. Finding genetic markers that may predispose to higher weight loss
under lifestyle intervention circumstances will have great potential as a helpful tool in a
clinical setting.
Study IV:
Ghrelin and the ghrelin receptor were expressed in PBMCs, but their expression was not
altered upon metabolic changes, thus making ghrelin expression unsuitable as a surrogate
marker for ghrelin metabolism in metabolic syndrome. Ghrelin was also expressed in adipose
tissue, but with very low intensity. Therefore, it is not anticipated that ghrelin would exert
autocrine effects in adipose tissue.
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Ghrelin plasma levels were not restored by weight loss in persons with metabolic
syndrome; instead, ghrelin concentrations further decreased in those not receiving counselling
regarding eating behaviour and physical activity habits.
Although numerous studies have been conducted, no clear picture yet exists on the
significance of ghrelin plasma levels. Ghrelin concentrations are paradoxically lower in
obesity and type 2 diabetes and metabolic syndrome; nevertheless, persons with those
diseases do not lose weight following a reduction in appetite-stimulating hormone levels, as
could be anticipated. However, the mechanisms controlling appetite and eating behaviour are
complicated and redundant, and supposedly do not function properly in persons with
metabolic diseases. Furthermore, environmental factors have a great influence in addition to
underlying genetic determinants. Nevertheless, the present study added important knowledge
concerning the role of ghrelin in obesity and insulin resistance, thus contributing one piece to
a puzzle which will hopefully be solved in the future.
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